{
    "paper_id": "b0d61d88edae2c7eed38a881e7e9da3182996e52",
    "metadata": {
        "title": "Antagonistes du r\u00e9cepteur CCR5 et infection par le VIH-1 : bases et cons\u00e9quences de cette approche th\u00e9rapeutique CCR5 antagonists and HIV-1 infection: Bases and consequences of this therapeutic approach",
        "authors": [
            {
                "first": "K",
                "middle": [
                    "C"
                ],
                "last": "Psomas",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institut de g\u00e9 n\u00e9 tique humaine",
                    "institution": "CNRS",
                    "location": {
                        "addrLine": "142, rue de la Cardonille",
                        "postCode": "34396, cedex 5",
                        "settlement": "Montpellier",
                        "country": "France"
                    }
                },
                "email": ":kcpsomas@igh.cnrs.fr"
            },
            {
                "first": "P",
                "middle": [],
                "last": "Corbeau",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institut de g\u00e9 n\u00e9 tique humaine",
                    "institution": "CNRS",
                    "location": {
                        "addrLine": "142, rue de la Cardonille",
                        "postCode": "34396, cedex 5",
                        "settlement": "Montpellier",
                        "country": "France"
                    }
                },
                "email": ""
            },
            {
                "first": "J",
                "middle": [],
                "last": "Reynes",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "La mol\u00e9cule CCR5 est un r\u00e9cepteur de chimiokines qui joue un r\u00f4le important en pathologie infectieuse : cor\u00e9cepteur des souches du VIH-1 \u00e0 tropisme R5, il est \u00e9galement impliqu\u00e9 dans la d\u00e9fense immunitaire contre certains agents transmissibles. Les antagonistes de CCR5 constituent une nouvelle approche th\u00e9rapeutique antir\u00e9trovirale. Trois inhibiteurs du CCR5 ont atteint les phases IIb et III de d\u00e9veloppement clinique : aplaviroc (GlaxoSmithKine), vicriviroc (Schering-Plough) et maraviroc (Pfizer). Le d\u00e9veloppement de l'aplaviroc a \u00e9t\u00e9 interrompu pour toxicit\u00e9 h\u00e9patique. Les essais ACTG 5211 et Motivate ont d\u00e9montr\u00e9 une am\u00e9lioration de la r\u00e9ponse antir\u00e9trovirale par l'addition respectivement de vicriviroc (actuellement en phase III) et de maraviroc (ayant d\u00e9j\u00e0 obtenu l'Autorisation de Mise sur le March\u00e9) \u00e0 un traitement optimis\u00e9 chez des patients en \u00e9chec th\u00e9rapeutique. Le r\u00f4le de cette nouvelle cible th\u00e9rapeutique dans les strat\u00e9gies de traitement initial, de substitution ou de sauvetage reste \u00e0 pr\u00e9ciser, de m\u00eame que leur int\u00e9r\u00eat chez des patients ayant une r\u00e9ponse immunovirologique dissoci\u00e9e, en immunod\u00e9presssion s\u00e9v\u00e8re ou infect\u00e9s par des souches \u00e0 tropisme non-R5. Plusieurs points sont \u00e9galement \u00e0 \u00e9claircir comme la tol\u00e9rance \u00e0 long terme, le risque d'induire une commutation R5-X4, en particulier dans les tissus, le risque d'interf\u00e9rer avec les r\u00e9ponses immunitaires, ainsi que l'impact d'une discordance de tropisme entre le plasma et les autres compartiments de l'organisme. # 2010 Elsevier Masson SAS. Tous droits r\u00e9serv\u00e9s.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Summary CCR5 molecule is a chemokine receptor with an important role in infectious diseases; not only is it the main coreceptor for HIV-1, but it has also been involved in the immune defense against various transmissible agents. CCR5 antagonists constitute a new class of antiretrovirals. Three molecules of this class have reached phases 2B and 3 of clinical development: aplaviroc (GlaxoSmithKine), vicriviroc (Schering-Plough) and maraviroc (Pfizer). The development of aplaviroc was stopped because of some cases of drug-induced hepatitis. In ACTG 5211 and Motivate trials, adding vicriviroc (in phase 3 trials) or maraviroc (now approved for clinical use) respectively to an optimized background regimen in treatment-experienced patients has resulted in a significant virologic benefit. The place of this new therapeutic class in strategies of initial, switch or rescue treatment needs further investigation, and its interest in immunological non-responders, in severe immunosuppressed patients or in subjects harbouring non-R5 HIV-1 strains, remains to be addressed. Major concerns about their use still remain, including long-term tolerability, the risk of inducing an R5 to X4 switch, particularly in compartments other than blood, and the risk of interfering with some immune responses. #",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "Bien que la th\u00e9rapeutique anti-VIH-1 comporte actuellement cinq classes antir\u00e9trovirales comprenant plus de 25 mol\u00e9cules, la recherche de nouveaux agents reste primordiale afin d'am\u00e9liorer l'observance m\u00e9dicamenteuse, de limiter la toxicit\u00e9 et de garantir une activit\u00e9 efficace prolong\u00e9e. Un certain nombre de mol\u00e9cules prometteuses sont en cours de d\u00e9veloppement, dans les classes d\u00e9j\u00e0 existantes (inhibiteurs de la transcriptase inverse, de la prot\u00e9ase virale et inhibiteurs de fusion) mais \u00e9galement dans de nouvelles classes (inhibiteurs de l'int\u00e9grase). Cependant, l'identification de traitements exploitant de nouvelles cibles du cycle antir\u00e9troviral demeure essentielle. En effet, la d\u00e9couverte du principal cor\u00e9cepteur du VIH-1, le r\u00e9cepteur de chimiokines CCR5 [1] [2] [3] [4] [5] , a ouvert de nouvelles possibilit\u00e9s th\u00e9rapeutiques, notamment des antagonistes de ce cor\u00e9cepteur. Dans cette revue, nous allons d\u00e9crire bri\u00e8vement les caract\u00e9ristiques biologiques du CCR5, les cons\u00e9quences virologiques et immunologiques de son blocage, ainsi que les caract\u00e9ristiques des principales mol\u00e9cules antir\u00e9trovirales le ciblant.",
            "cite_spans": [
                {
                    "start": 770,
                    "end": 773,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 774,
                    "end": 777,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 778,
                    "end": 781,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 782,
                    "end": 785,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 786,
                    "end": 789,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Le CCR5, r\u00e9cepteur de chimiokines et cor\u00e9cepteur du VIH-1 En 1996, a \u00e9t\u00e9 identifi\u00e9e la mol\u00e9cule CXCR4, r\u00e9cepteur de chimiokines dont le seul ligand connu est la chimiokine CXCL12 (SDF-1), en tant que cor\u00e9cepteur des souches du VIH-1 \u00e0 \u00ab tropisme lymphocytaire T \u00bb ou \u00ab tropisme X4 \u00bb [6] utilis\u00e9 en compl\u00e9ment du r\u00e9cepteur CD4 (Tableau 1). Peu apr\u00e8s, a \u00e9t\u00e9 identifi\u00e9e la mol\u00e9cule CCR5 en tant que cor\u00e9cepteur des souches du VIH-1 \u00e0 \u00ab tropisme macrophagique M \u00bb ou \u00ab tropisme R5 \u00bb [1] [2] [3] [4] [5] . Le CCR5 est un r\u00e9cepteur membranaire coupl\u00e9 aux prot\u00e9ines G (RCPG) qui lie des chimiokines de la famille C-C, essentiellement le CCL3 (MIP-1a), le CCL4 (MIP-1b) et le CCL5 (RANTES) [7] . D'autres RCPG, notamment CCR3, CCR8 et CXCR1, peuvent \u00eatre utilis\u00e9s en tant que cor\u00e9cepteurs du VIH-1 in vitro, mais leur r\u00f4le reste incertain in vivo.",
            "cite_spans": [
                {
                    "start": 283,
                    "end": 286,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 479,
                    "end": 482,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 483,
                    "end": 486,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 487,
                    "end": 490,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 491,
                    "end": 494,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 495,
                    "end": 498,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 682,
                    "end": 685,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Comme tous les RCPG, le CCR5 et le CXCR4 sont constitu\u00e9s d'un domaine N-terminal extracellulaire, de sept domaines transmembranaires (formant trois boucles extra-et trois boucles intracellulaires) ainsi que d'un domaine C-terminal intracytoplasmique (Fig. 1) . Des \u00e9tudes par mutagen\u00e8se, utilisation de peptides homologues, d'anticorps monoclonaux ou de mol\u00e9cules hybrides entre le CCR5 et d'autres r\u00e9cepteurs de chimiokines, ont montr\u00e9 que le domaine N-terminal (surtout les 20 premiers aminoacides) et les boucles extracellulaires du CCR5 (essentiellement la deuxi\u00e8me) participent \u00e0 la liaison de la glycoprot\u00e9ine r\u00e9trovirale gp120 avec le CCR5, la fusion membranaire entre la cellule et la particule virale et l'entr\u00e9e du VIH-1 dans la cellule. Il est \u00e0 noter qu'il existe une certaine variabilit\u00e9 dans la fa\u00e7on dont les souches virales interagissent avec la mol\u00e9cule de CCR5. En effet, des diff\u00e9rences de sites de liaison ont \u00e9t\u00e9 observ\u00e9es entre les souches \u00e0 tropisme R5 ou dual (R5X4) [8] , les souches VIH-1 des soustypes B ou non-B [9] , ainsi que les souches des sous-types B entre elles. Le chevauchement du site de liaison de la gp120 avec le site de liaison des chimiokines est partiel, ce qui peut expliquer le fait que seuls certains antagonistes des CCR5 emp\u00eachent la liaison des chimiokines. D'un point de vue quantitatif, Kuhmann et al. [10] ont estim\u00e9 que quatre \u00e0 six mol\u00e9cules de CCR5 s'assemblent autour du virion afin de former un complexe permettant l'infection. Les mol\u00e9cules de CD4 et de CCR5 sont coexprim\u00e9es sur les cellules T CD4+, les cellules dendritiques ainsi que sur les monocytes et macrophages. L'importance de la pr\u00e9sence du CCR5 pour l'infection par le VIH-1 in vivo est d\u00e9montr\u00e9e par le fait que des sujets homozygotes pour l'all\u00e8le CCR5-D32 (d\u00e9fini par une d\u00e9l\u00e9tion de 32 paires de bases responsable de l'apparition d'un codon stop pr\u00e9matur\u00e9), codant pour une prot\u00e9ine CCR5 tronqu\u00e9e qui n'est pas exprim\u00e9e \u00e0 la surface cellulaire ( Fig. 1) , sont habituellement r\u00e9sistants \u00e0 l'infection par le VIH-1 [11, 12] .",
            "cite_spans": [
                {
                    "start": 991,
                    "end": 994,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 1040,
                    "end": 1043,
                    "text": "[9]",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 1354,
                    "end": 1358,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 2039,
                    "end": 2043,
                    "text": "[11,",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 2044,
                    "end": 2047,
                    "text": "12]",
                    "ref_id": "BIBREF11"
                }
            ],
            "ref_spans": [
                {
                    "start": 250,
                    "end": 258,
                    "text": "(Fig. 1)",
                    "ref_id": null
                },
                {
                    "start": 1971,
                    "end": 1978,
                    "text": "Fig. 1)",
                    "ref_id": null
                }
            ],
            "section": "Introduction"
        },
        {
            "text": "Quel que soit le mode de transmission, les virus \u00e0 tropisme R5 (souches de VIH-1 utilisant pr\u00e9f\u00e9rentiellement le cor\u00e9cepteur CCR5) peuvent \u00eatre d\u00e9tect\u00e9s \u00e0 tous les stades de l'infection, tandis que les virus \u00e0 tropisme X4 (souches utilisant le cor\u00e9cepteur CXCR4) ou dual R5/X4 (souches pouvant utiliser soit CCR5, soit CXCR4) sont isol\u00e9s chez un tiers \u00e0 la moiti\u00e9 des patients, surtout aux stades avanc\u00e9s de l'infection (Tableau 1) [13] . Ainsi, chez des patients na\u00effs de tout traitement antir\u00e9troviral, une \u00e9tude a rapport\u00e9 que les souches R5 sont d\u00e9tect\u00e9es de fa\u00e7on exclusive chez environ 90 % des sujets ayant un nombre de cellules T CD4+ sup\u00e9rieur \u00e0 200/mm 3 , chez environ 70 % des sujets ayant un nombre de cellules T CD4+ entre 25 et 200/mm 3 et chez environ 45 % des sujets avec un nombre de cellules T CD4+ inf\u00e9rieur \u00e0 25/mm 3 [14] . La pr\u00e9dominance des souches R5 dans les stades pr\u00e9coces de la maladie et l'\u00e9mergence des souches X4 chez certains des patients dans les stades plus tardifs, qui est corr\u00e9l\u00e9e \u00e0 une progression plus rapide de la maladie [15] [16] [17] , sont des ph\u00e9nom\u00e8nes encore mal expliqu\u00e9s. De nombreux facteurs peuvent participer \u00e0 la pr\u00e9dominance des souches R5 pendant la plus grande partie de la phase chronique de l'infection \u00e0 VIH-1. Certains auteurs soutiennent l'id\u00e9e que la r\u00e9ponse immunitaire humorale [18] ou cytotoxique [19] est plus efficace contre les souches X4, ainsi le syst\u00e8me immunitaire devrait-il \u00eatre affaibli par les souches R5 afin de permettre l'expansion des souches X4. D'autres pensent que cette pr\u00e9dominance est due \u00e0 une plus grande capacit\u00e9 r\u00e9plicative des souches R5. Cette derni\u00e8re pourrait \u00eatre le r\u00e9sultat d'une plus grande densit\u00e9 de CCR5 \u00e0 la surface des cellules T CD4+, d'une proximit\u00e9 st\u00e9rique de la mol\u00e9cule CCR5 avec le r\u00e9cepteur CD4 [20] , d'une affinit\u00e9 plus forte de la gp120 des souches R5 pour le cor\u00e9cepteur CCR5 [21] ou d'un pouvoir pathog\u00e8ne plus important des souches X4 [22] .",
            "cite_spans": [
                {
                    "start": 432,
                    "end": 436,
                    "text": "[13]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 837,
                    "end": 841,
                    "text": "[14]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 1062,
                    "end": 1066,
                    "text": "[15]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 1067,
                    "end": 1071,
                    "text": "[16]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 1072,
                    "end": 1076,
                    "text": "[17]",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 1342,
                    "end": 1346,
                    "text": "[18]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 1362,
                    "end": 1366,
                    "text": "[19]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 1806,
                    "end": 1810,
                    "text": "[20]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 1891,
                    "end": 1895,
                    "text": "[21]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1952,
                    "end": 1956,
                    "text": "[22]",
                    "ref_id": "BIBREF21"
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Le r\u00e9cepteur CCR5 est exprim\u00e9 \u00e0 la surface de certaines cellules h\u00e9matopo\u00ef\u00e9tiques (cellules dendritiques immatures, monocytes et macrophages, cellules T CD4+ ou CD8+) [23, 24] , des cellules du syst\u00e8me nerveux central (neurones, astrocytes et cellules microgliales), de certaines cellules \u00e9pith\u00e9liales ou endoth\u00e9liales, de cellules musculaires lisses vasculaires, ainsi que de fibroblastes [25] . Par cytom\u00e9trie de flux, on a pu quantifier le nombre des mol\u00e9cules de CCR5 \u00e0 la membrane de chaque cellule T CD4+ qui se situe entre 4000 et 24 000 en dehors des sujets homozygotes pour la mutation D32 [26] . Cette densit\u00e9 en CCR5 est constante pour un individu donn\u00e9, ce qui permet de distinguer des sujets ayant une forte ou une faible densit\u00e9 membranaire en CCR5 [26] . Des polymorphismes g\u00e9n\u00e9tiques dans le promoteur du g\u00e8ne CCR5 responsables d'une expression quantitativement diff\u00e9rente du CCR5 \u00e0 la surface cellulaire sont significativement corr\u00e9l\u00e9s \u00e0 la progression plus ou moins rapide de l'infection par le VIH-1 [27] [28] [29] .",
            "cite_spans": [
                {
                    "start": 167,
                    "end": 171,
                    "text": "[23,",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 172,
                    "end": 175,
                    "text": "24]",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 390,
                    "end": 394,
                    "text": "[25]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 599,
                    "end": 603,
                    "text": "[26]",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 763,
                    "end": 767,
                    "text": "[26]",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 1019,
                    "end": 1023,
                    "text": "[27]",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 1024,
                    "end": 1028,
                    "text": "[28]",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 1029,
                    "end": 1033,
                    "text": "[29]",
                    "ref_id": "BIBREF28"
                }
            ],
            "ref_spans": [],
            "section": "Expression membranaire du CCR5"
        },
        {
            "text": "Les chimiokines qui se lient au r\u00e9cepteur CCR5 induisent son endocytose au sein d'endosomes primaires, suivie du recyclage du r\u00e9cepteur \u00e0 la surface cellulaire. Le fait que la densit\u00e9 membranaire en CCR5 sur les cellules T CD4+ soit inversement corr\u00e9l\u00e9e \u00e0 la quantit\u00e9 d'ARN messager du CCL5 pr\u00e9sent dans les cellules sanguines mononucl\u00e9es p\u00e9riph\u00e9riques [30] est en faveur d'un mod\u00e8le o\u00f9 la concentration plasmatique des chimiokines liant CCR5 r\u00e9gulerait le niveau d'expression membranaire du CCR5. Dans le m\u00eame sens, l'administration d'un antagoniste de CCR5 emp\u00eachant l'interaction CCR5-chimiokine \u00e0 des volontaires sains a comme r\u00e9sultat l'augmentation de la densit\u00e9 membranaire en CCR5 \u00e0 la surface des cellules T CD4+ [30] . En l'absence de ligand, il existe un cycle de renouvellement naturel du CCR5 qui a une demi-vie membranaire de quelques heures [31] .",
            "cite_spans": [
                {
                    "start": 353,
                    "end": 357,
                    "text": "[30]",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 722,
                    "end": 726,
                    "text": "[30]",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 856,
                    "end": 860,
                    "text": "[31]",
                    "ref_id": "BIBREF30"
                }
            ],
            "ref_spans": [],
            "section": "Expression membranaire du CCR5"
        },
        {
            "text": "L'expression du CCR5 \u00e0 la surface des cellules T CD4+ peut \u00eatre influenc\u00e9e par diff\u00e9rents facteurs. On observe une augmentation de la densit\u00e9 en CCR5 en pr\u00e9sence de certaines cytokines (IL-2, IL-15, IFN-g) [32] ou \u00e0 la suite de stimulations antig\u00e9niques [33] . Inversement, la densit\u00e9 en CCR5 diminue apr\u00e8s stimulation via la mol\u00e9cule CD28 [34] , en pr\u00e9sence d'autres cytokines (IL-4, IL-10, IL-16) [32] ou de progest\u00e9rone [35] .",
            "cite_spans": [
                {
                    "start": 206,
                    "end": 210,
                    "text": "[32]",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 254,
                    "end": 258,
                    "text": "[33]",
                    "ref_id": "BIBREF32"
                },
                {
                    "start": 340,
                    "end": 344,
                    "text": "[34]",
                    "ref_id": "BIBREF33"
                },
                {
                    "start": 399,
                    "end": 403,
                    "text": "[32]",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 423,
                    "end": 427,
                    "text": "[35]",
                    "ref_id": "BIBREF34"
                }
            ],
            "ref_spans": [],
            "section": "Expression membranaire du CCR5"
        },
        {
            "text": "Il est \u00e0 noter que la densit\u00e9 membranaire en CCR5 augmente pendant la primo-infection VIH-1, puis reste stable au cours du temps, au moins durant la phase asymptomatique de l'infection [26] . Inversement, le pourcentage des cellules T CD4+ exprimant le cor\u00e9cepteur CCR5 \u00e0 leur surface n'est pas stable au cours du temps, aussi bien chez les sujets infect\u00e9s par le VIH-1 que les sujets non infect\u00e9s.",
            "cite_spans": [
                {
                    "start": 185,
                    "end": 189,
                    "text": "[26]",
                    "ref_id": "BIBREF25"
                }
            ],
            "ref_spans": [],
            "section": "Expression membranaire du CCR5"
        },
        {
            "text": "Le CCR5 n'est pas uniquement un r\u00e9cepteur responsable de ph\u00e9nom\u00e8nes de chimiotactisme, mais \u00e9galement un r\u00e9cepteur responsable de ph\u00e9nom\u00e8nes de coactivation cellulaire Figure 1 Expression de CCR5 \u00e0 la surface de la cellule. Le g\u00e8ne sauvage avec expression membranaire normale du r\u00e9cepteur est repr\u00e9sent\u00e9 \u00e0 gauche. \u00c0 droite, le g\u00e8ne CCR5D32 code pour un r\u00e9cepteur tronqu\u00e9 qui n'est pas exprim\u00e9 \u00e0 la surface cellulaire. CCR5 expression at the cell surface. Wild-type gene is responsible for a normal level of expression of the receptor and is represented at the left part of the figure. At the right part of the figure is represented the deleted CCR5D32 gene, which encodes a truncated receptor that is not expressed at the cell surface.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 168,
                    "end": 176,
                    "text": "Figure 1",
                    "ref_id": null
                }
            ],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "( Fig. 2 ). En effet, la chimiokine RANTES est capable d'induire l'expression de marqueurs d'activation \u00e0 la surface des cellules T primaires d'origine murine in vitro ; de plus, elle est capable d'engendrer une prolif\u00e9ration cellulaire T, une production cytokinique (CCL3, IFNg, IL-2) et une division cellulaire accrues en r\u00e9ponse \u00e0 une stimulation antig\u00e9nique in vivo chez la souris [36] .",
            "cite_spans": [
                {
                    "start": 385,
                    "end": 389,
                    "text": "[36]",
                    "ref_id": "BIBREF35"
                }
            ],
            "ref_spans": [
                {
                    "start": 2,
                    "end": 8,
                    "text": "Fig. 2",
                    "ref_id": null
                }
            ],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "Plus sp\u00e9cifiquement, le CCR5 est un acteur de l'immunit\u00e9 cellulaire ; il est exprim\u00e9 \u00e0 la surface des cellules T CD4+ de type Th1, c'est-\u00e0-dire les cellules T produisant les cytokines de type 1 (IL-2 et IFNg) qui favorisent la r\u00e9ponse immunitaire de type cellulaire [37] .",
            "cite_spans": [
                {
                    "start": 266,
                    "end": 270,
                    "text": "[37]",
                    "ref_id": "BIBREF36"
                }
            ],
            "ref_spans": [],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "Pourtant la mol\u00e9cule CCR5 ne para\u00eet pas \u00eatre physiologiquement indispensable. Des souris ayant une d\u00e9l\u00e9tion cibl\u00e9e du g\u00e8ne CCR5 se d\u00e9veloppent normalement dans un environnement d\u00e9pourvu d'agents pathog\u00e8nes et pr\u00e9sentent peu de perturbations de leur s\u00e9cr\u00e9tion cytokinique. De m\u00eame, les sujets homozygotes pour l'all\u00e8le CCR5-D32, qui n'ont pas d'expression membranaire de CCR5, ne pr\u00e9sentent pas de pathologie particuli\u00e8re, \u00e0 part une pr\u00e9valence plus importante d'hypertension art\u00e9rielle [38, 39] .",
            "cite_spans": [
                {
                    "start": 486,
                    "end": 490,
                    "text": "[38,",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 491,
                    "end": 494,
                    "text": "39]",
                    "ref_id": "BIBREF38"
                }
            ],
            "ref_spans": [],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "M\u00eame si le r\u00e9cepteur CCR5 n'est pas indispensable dans des conditions physiologiques, il para\u00eet \u00eatre impliqu\u00e9 dans plusieurs situations pathologiques.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "Le r\u00f4le du r\u00e9cepteur CCR5 en pathologie Le r\u00f4le du CCR5 en maladies infectieuses En dehors du r\u00f4le de cor\u00e9cepteur pour le VIH-1, la mol\u00e9cule CCR5 est impliqu\u00e9e dans la d\u00e9fense immunitaire contre un certain nombre d'agents transmissibles. Ainsi, la r\u00e9ponse immunitaire contre Listeria monocytogenes [40] , Cryptococcus neoformans [41] , Toxoplasma gondii [42] , le virus Influenza A [43] , Herpes simplex virus de type 2 [44] , Trypanosoma cruzi [45] et Chlamydia trachomatis [46] est-elle compromise chez des souris d\u00e9ficientes en CCR5 ?",
            "cite_spans": [
                {
                    "start": 298,
                    "end": 302,
                    "text": "[40]",
                    "ref_id": "BIBREF39"
                },
                {
                    "start": 329,
                    "end": 333,
                    "text": "[41]",
                    "ref_id": "BIBREF40"
                },
                {
                    "start": 354,
                    "end": 358,
                    "text": "[42]",
                    "ref_id": "BIBREF41"
                },
                {
                    "start": 382,
                    "end": 386,
                    "text": "[43]",
                    "ref_id": "BIBREF42"
                },
                {
                    "start": 420,
                    "end": 424,
                    "text": "[44]",
                    "ref_id": "BIBREF43"
                },
                {
                    "start": 445,
                    "end": 449,
                    "text": "[45]",
                    "ref_id": "BIBREF44"
                },
                {
                    "start": 475,
                    "end": 479,
                    "text": "[46]",
                    "ref_id": "BIBREF45"
                }
            ],
            "ref_spans": [],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "Chez l'homme, des variations g\u00e9n\u00e9tiques du promoteur de CCR5 sont associ\u00e9es \u00e0 des formes s\u00e9v\u00e8res de bronchiolites dues au virus respiratoire syncytial [47] , et le d\u00e9ficit complet en CCR5 conf\u00e8re un risque augment\u00e9 d'infection symptomatique s\u00e9v\u00e8re par deux Flaviviridae, le virus de la fi\u00e8vre de West-Nile [48] et le virus de la m\u00e9ningo-enc\u00e9phalite saisonni\u00e8re europ\u00e9enne \u00e0 tiques (Tick Born Encephalitis) [49] . De plus, certains auteurs ont rapport\u00e9 que le ph\u00e9notype homozygote CCR5-D32 est plus souvent rencontr\u00e9 chez les sujets infect\u00e9s par le virus de l'h\u00e9patite C [50] , et que dans ce cas les sujets ont des charges virales plasmatiques plus \u00e9lev\u00e9es [50] , des niveaux plasmatiques de transaminases ALAT plus importants [39] et une r\u00e9ponse faible au traitement par IFNa [51] . Cependant, ces derni\u00e8res observations sont controvers\u00e9es [52] [53] [54] [55] [56] .",
            "cite_spans": [
                {
                    "start": 151,
                    "end": 155,
                    "text": "[47]",
                    "ref_id": "BIBREF46"
                },
                {
                    "start": 306,
                    "end": 310,
                    "text": "[48]",
                    "ref_id": "BIBREF47"
                },
                {
                    "start": 406,
                    "end": 410,
                    "text": "[49]",
                    "ref_id": "BIBREF48"
                },
                {
                    "start": 570,
                    "end": 574,
                    "text": "[50]",
                    "ref_id": "BIBREF49"
                },
                {
                    "start": 657,
                    "end": 661,
                    "text": "[50]",
                    "ref_id": "BIBREF49"
                },
                {
                    "start": 727,
                    "end": 731,
                    "text": "[39]",
                    "ref_id": "BIBREF38"
                },
                {
                    "start": 777,
                    "end": 781,
                    "text": "[51]",
                    "ref_id": "BIBREF50"
                },
                {
                    "start": 841,
                    "end": 845,
                    "text": "[52]",
                    "ref_id": "BIBREF51"
                },
                {
                    "start": 846,
                    "end": 850,
                    "text": "[53]",
                    "ref_id": "BIBREF52"
                },
                {
                    "start": 851,
                    "end": 855,
                    "text": "[54]",
                    "ref_id": "BIBREF53"
                },
                {
                    "start": 856,
                    "end": 860,
                    "text": "[55]",
                    "ref_id": "BIBREF54"
                },
                {
                    "start": 861,
                    "end": 865,
                    "text": "[56]",
                    "ref_id": "BIBREF55"
                }
            ],
            "ref_spans": [],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "Inversement, le r\u00e9cepteur CCR5 pourrait jouer un r\u00f4le p\u00e9joratif dans d'autres pathologies impliquant la r\u00e9ponse immunitaire antimicrobienne elle-m\u00eame. Par exemple, les souris CCR5 \u00c0/\u00c0 paraissent moins susceptibles au neuropaludisme gr\u00e2ce \u00e0 un d\u00e9faut de l'accumulation leucocytaire dans le cerveau [57] , pr\u00e9sentent une d\u00e9my\u00e9linisation moins s\u00e9v\u00e8re apr\u00e8s infection par un coronavirus neurotrope (du fait d'une diminution de la mobilisation macrophagique dans le syst\u00e8me nerveux central) [58] et semblent prot\u00e9g\u00e9es contre le choc endotoxique induit par le lipopolysaccharide (LPS) [40] .",
            "cite_spans": [
                {
                    "start": 297,
                    "end": 301,
                    "text": "[57]",
                    "ref_id": "BIBREF56"
                },
                {
                    "start": 486,
                    "end": 490,
                    "text": "[58]",
                    "ref_id": "BIBREF57"
                },
                {
                    "start": 579,
                    "end": 583,
                    "text": "[40]",
                    "ref_id": "BIBREF39"
                }
            ],
            "ref_spans": [],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "Toutes ces observations prouvent que d'un c\u00f4t\u00e9 le r\u00e9cepteur CCR5 participe \u00e0 la d\u00e9fense immunitaire contre certains agents infectieux mais que, de l'autre, ce m\u00eame r\u00e9cepteur est \u00e0 l'origine de ph\u00e9nom\u00e8nes immunitaires pathog\u00e8nes induits par d'autres agents.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "Le r\u00f4le du r\u00e9cepteur CCR5 en pathologie non infectieuse Le CCR5 intervient probablement dans la r\u00e9ponse immunitaire et l'infiltration par des cellules mononucl\u00e9\u00e9es dans plusieurs pathologies auto-immunes, dont plus particuli\u00e8rement la scl\u00e9rose en plaques, le diab\u00e8te de type I, les colites et la polyarthrite rhumato\u00efde. Par exemple, de multiples arguments plaident en faveur de la responsabilit\u00e9 du CCR5 dans le recrutement des monocytes et des cellules Th1 dans les articulations inflammatoires durant la polyarthrite rhumato\u00efde. De cette fa\u00e7on, des sujets h\u00e9t\u00e9rozygotes CCR5-D32 pourraient \u00eatre partiellement prot\u00e9g\u00e9s contre la polyarthrite rhumato\u00efde [59] [60] [61] et plus particuli\u00e8rement contre les formes s\u00e9v\u00e8res de cette maladie [62] . L'expression de CCR5 para\u00eet faciliter le d\u00e9veloppement de l'ath\u00e9roscl\u00e9rose. Ainsi, chez des souris susceptibles de d\u00e9velopper une ath\u00e9roscl\u00e9rose, le d\u00e9ficit en CCR5 est protecteur [63, 64] et les antagonistes de CCR5 r\u00e9duisent la formation des plaques d'ath\u00e9rome [65] .",
            "cite_spans": [
                {
                    "start": 655,
                    "end": 659,
                    "text": "[59]",
                    "ref_id": "BIBREF58"
                },
                {
                    "start": 660,
                    "end": 664,
                    "text": "[60]",
                    "ref_id": "BIBREF59"
                },
                {
                    "start": 665,
                    "end": 669,
                    "text": "[61]",
                    "ref_id": "BIBREF60"
                },
                {
                    "start": 738,
                    "end": 742,
                    "text": "[62]",
                    "ref_id": "BIBREF61"
                },
                {
                    "start": 925,
                    "end": 929,
                    "text": "[63,",
                    "ref_id": "BIBREF62"
                },
                {
                    "start": 930,
                    "end": 933,
                    "text": "64]",
                    "ref_id": "BIBREF63"
                },
                {
                    "start": 1008,
                    "end": 1012,
                    "text": "[65]",
                    "ref_id": "BIBREF64"
                }
            ],
            "ref_spans": [],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "Le CCR5 est \u00e9galement impliqu\u00e9 dans les m\u00e9canismes de rejet de greffe. Ainsi, Fischereder et al. ont remarqu\u00e9 qu'il y avait une augmentation de la survie des transplants r\u00e9naux chez les sujets homozygotes CCR5-D32 [66] ; Abdi et al. ont observ\u00e9 un risque de rejet aigu de greffe r\u00e9nale diminu\u00e9 chez des sujets homozygotes pour la mutation CCR5-59029-A/G du promoteur de CCR5, r\u00e9sultant en une faible expression de CCR5 [67] .",
            "cite_spans": [
                {
                    "start": 214,
                    "end": 218,
                    "text": "[66]",
                    "ref_id": "BIBREF65"
                },
                {
                    "start": 419,
                    "end": 423,
                    "text": "[67]",
                    "ref_id": "BIBREF66"
                }
            ],
            "ref_spans": [],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "De plus, Hall et al. ont observ\u00e9 une association entre CCR5-D32 et un risque r\u00e9duit d'asthme [68] , cependant cette association n'a pas \u00e9t\u00e9 retrouv\u00e9e par d'autres auteurs [69] [70] [71] .",
            "cite_spans": [
                {
                    "start": 93,
                    "end": 97,
                    "text": "[68]",
                    "ref_id": "BIBREF67"
                },
                {
                    "start": 171,
                    "end": 175,
                    "text": "[69]",
                    "ref_id": "BIBREF68"
                },
                {
                    "start": 176,
                    "end": 180,
                    "text": "[70]",
                    "ref_id": "BIBREF69"
                },
                {
                    "start": 181,
                    "end": 185,
                    "text": "[71]",
                    "ref_id": "BIBREF70"
                }
            ],
            "ref_spans": [],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "Enfin, le CCR5 a un r\u00f4le ambivalent dans le cancer ; d'un c\u00f4t\u00e9, il pourrait \u00eatre responsable de signaux de prolif\u00e9ration Figure 2 Le CCR5 en tant que mol\u00e9cule de coactivation cellulaire : il induit l'expression de marqueurs d'activation, il peut engendrer la prolif\u00e9ration cellulaire, la production de cytokines et la division cellulaire accrue. CCR5 is also a coactivation receptor: it induces the expression of activation markers, may induce cellular proliferation, cytokine production and active cell division.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 121,
                    "end": 129,
                    "text": "Figure 2",
                    "ref_id": null
                }
            ],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "[72], d'invasion et de m\u00e9tastase [73] , ce qui a comme cons\u00e9quence un effet protumoral, et de l'autre c\u00f4t\u00e9, il pourrait \u00eatre \u00e0 l'origine d'un effet antitumoral par l'interm\u00e9diaire des leucocytes infiltrant la tumeur et exprimant le CCR5 [74] . Un autre effet antitumoral plus direct a \u00e9t\u00e9 rapport\u00e9 par Ma\u00f1es et al., qui ont mis en \u00e9vidence une survie inf\u00e9rieure chez des patients ayant un cancer du sein et porteurs de l'all\u00e8le CCR5D32 [75] .",
            "cite_spans": [
                {
                    "start": 33,
                    "end": 37,
                    "text": "[73]",
                    "ref_id": "BIBREF72"
                },
                {
                    "start": 237,
                    "end": 241,
                    "text": "[74]",
                    "ref_id": "BIBREF73"
                },
                {
                    "start": 436,
                    "end": 440,
                    "text": "[75]",
                    "ref_id": "BIBREF74"
                }
            ],
            "ref_spans": [],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "Cons\u00e9quences potentielles de l'usage des antagonistes CCR5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "R\u00f4le physiologique du r\u00e9cepteur CCR5"
        },
        {
            "text": "Cons\u00e9quences positives : effet anti-VIH-1. Les antagonistes de CCR5 sont classiquement d\u00e9crits comme des inhibiteurs de l'entr\u00e9e du VIH-1 dans la cellule. En r\u00e9alit\u00e9, ils poss\u00e8dent trois effets antiviraux surajout\u00e9s. Premi\u00e8rement, ils inhibent le d\u00e9veloppement de syncytia, r\u00e9sultat de la fusion entre cellules infect\u00e9es et non infect\u00e9es et ayant \u00e9t\u00e9 consid\u00e9r\u00e9 comme une des causes de la chute du nombre des lymphocytes T CD4+ chez les sujets infect\u00e9s. Deuxi\u00e8mement, ils inhibent l'apoptose induite par la gp120, qui constitue un autre m\u00e9canisme potentiel de destruction des cellules T CD4+. L'intensit\u00e9 de cette apoptose d\u00e9pend de la densit\u00e9 membranaire de CCR5 [76] . Enfin, il a \u00e9t\u00e9 d\u00e9montr\u00e9 que les antagonistes de CCR5 sont capables d'agir en intracellulaire en pr\u00e9venant l'interaction entre la gp120 et le CCR5 qui a \u00e9galement comme cons\u00e9quence la lyse cellulaire [77] .",
            "cite_spans": [
                {
                    "start": 663,
                    "end": 667,
                    "text": "[76]",
                    "ref_id": "BIBREF75"
                },
                {
                    "start": 870,
                    "end": 874,
                    "text": "[77]",
                    "ref_id": "BIBREF76"
                }
            ],
            "ref_spans": [],
            "section": "Cons\u00e9quences virales"
        },
        {
            "text": "Au total, les antagonistes de CCR5 inhibent non seulement la r\u00e9plication du VIH-1, mais diminuent \u00e9galement la cytopathog\u00e9nicit\u00e9 provoqu\u00e9e par la r\u00e9plication virale.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cons\u00e9quences virales"
        },
        {
            "text": "Enfin, il a \u00e9t\u00e9 d\u00e9montr\u00e9 in vitro que l'action des antagonistes CCR5 est synergique avec celle des autres traitements antir\u00e9troviraux [78] . Cette observation est concordante avec celle de Gervaix et al. et Vincent et al. qui mettent en \u00e9vidence une r\u00e9ponse th\u00e9rapeutique d\u00e9pendante de la densit\u00e9 membranaire en CCR5 des cellules T CD4+ [79, 80] . En cas d'utilisation des antagonistes CCR5, l'augmentation de l'efficacit\u00e9 th\u00e9rapeutique antir\u00e9trovirale pourrait \u00eatre due \u00e0 une diminution de la densit\u00e9 fonctionnelle de CCR5 qui est occup\u00e9 par les antagonistes. Cela est particuli\u00e8rement vrai pour les inhibiteurs de fusion, dans la mesure o\u00f9 les antagonistes de CCR5 pourraient prolonger le temps de contact de la gp41 avec ces m\u00e9dicaments [81] . Les travaux d'Heredia et al. ont d'ailleurs sugg\u00e9r\u00e9 que l'efficacit\u00e9 de l'enfuvirtide est inversement corr\u00e9l\u00e9e \u00e0 la densit\u00e9 en CCR5 [82] .",
            "cite_spans": [
                {
                    "start": 134,
                    "end": 138,
                    "text": "[78]",
                    "ref_id": "BIBREF77"
                },
                {
                    "start": 337,
                    "end": 341,
                    "text": "[79,",
                    "ref_id": "BIBREF78"
                },
                {
                    "start": 342,
                    "end": 345,
                    "text": "80]",
                    "ref_id": "BIBREF79"
                },
                {
                    "start": 740,
                    "end": 744,
                    "text": "[81]",
                    "ref_id": "BIBREF80"
                },
                {
                    "start": 879,
                    "end": 883,
                    "text": "[82]",
                    "ref_id": "BIBREF81"
                }
            ],
            "ref_spans": [],
            "section": "Cons\u00e9quences virales"
        },
        {
            "text": "Commutation de R5 \u00e0 X4. Chez un sujet infect\u00e9, il existe une comp\u00e9tition permanente entre les diff\u00e9rentes souches de VIH-1. En ce qui concerne les souches R5 et X4, cette comp\u00e9tition pourrait \u00eatre pour les cellules cibles, dans la mesure o\u00f9 34 \u00e0 76 % des cellules T CD4+ coexpriment CCR5 et CXCR4 [83] . Cette comp\u00e9tition n'est pourtant que relative car jusqu'\u00e0 60 % des cellules T CD4+CXCR4+ sont CCR5\u00c0, ce qui laisse sous-entendre que la prolif\u00e9ration des souches X4 pourrait ne pas \u00eatre inhib\u00e9e par la production des souches R5 [83] .",
            "cite_spans": [
                {
                    "start": 297,
                    "end": 301,
                    "text": "[83]",
                    "ref_id": "BIBREF82"
                },
                {
                    "start": 531,
                    "end": 535,
                    "text": "[83]",
                    "ref_id": "BIBREF82"
                }
            ],
            "ref_spans": [],
            "section": "Cons\u00e9quences virales"
        },
        {
            "text": "Dans ce contexte, la question majeure est de savoir si l'utilisation des antagonistes de CCR5 risque de provoquer une commutation des souches R5 vers les souches X4 (Fig. 3) , ce qui pourrait \u00eatre \u00e0 l'origine d'un \u00e9chec virologique et aggraver la pathog\u00e9nicit\u00e9 virale. En effet, comme on l'a mentionn\u00e9 ci-dessus, les causes de la modification du tropisme des souches du VIH-1 au cours de l'\u00e9volution de la maladie ne sont pas \u00e9lucid\u00e9es. En particulier, un bas niveau d'expression du r\u00e9cepteur CCR5 peut-il favoriser cet \u00e9v\u00e8nement ? Selon la th\u00e9orie de la comp\u00e9tition, une diminution de la densit\u00e9 en CCR5 pourrait induire la commutation en all\u00e9geant la pression sur les souches virales X4. De l'autre c\u00f4t\u00e9, on peut penser qu'une forte densit\u00e9 membranaire en CCR5 pourrait au contraire \u00eatre \u00e0 l'origine d'un haut degr\u00e9 de r\u00e9plication des souches R5, et par cons\u00e9quent d'une plus grande pr\u00e9valence de mutations, qui pourraient engendrer cette commutation de R5 en X4. Enfin, la pression th\u00e9rapeutique pourrait d\u00e9masquer des populations virales \u00e0 tropisme X4, pr\u00e9existant \u00e0 bas niveau et non d\u00e9tect\u00e9es par les tests de tropisme standard. Cela est sugg\u00e9r\u00e9 par le fait que les souches R5X4 et X4, d\u00e9tect\u00e9es au moment de l'\u00e9chec virologique sous antagoniste de CCR5, sont phylog\u00e9n\u00e9tiquement distinctes des souches R5 initiales [84] .",
            "cite_spans": [
                {
                    "start": 1321,
                    "end": 1325,
                    "text": "[84]",
                    "ref_id": "BIBREF83"
                }
            ],
            "ref_spans": [
                {
                    "start": 165,
                    "end": 173,
                    "text": "(Fig. 3)",
                    "ref_id": "FIGREF0"
                }
            ],
            "section": "Cons\u00e9quences virales"
        },
        {
            "text": "Chez les patients h\u00e9t\u00e9rozygotes pour l'all\u00e8le CCR5-D32, ayant une faible densit\u00e9 membranaire en CCR5, une plus grande incidence de commutation R5!X4 n'est pas \u00e9tablie. En effet, de Roda Husman et al. ont rapport\u00e9 que la commutation est plus tardive chez les patients h\u00e9t\u00e9rozygotes pour CCR5-D32 comparativement aux sujets homozygotes pour CCR5 wt [85] . Au contraire, D'Aquila et al. [86] et Zhang et al. [87] ont remarqu\u00e9 que le ph\u00e9notype X4 \u00e9tait plus fr\u00e9quent chez les sujets h\u00e9t\u00e9rozygotes pour CCR5-D32 que chez les homozygotes pour l'all\u00e8le sauvage.",
            "cite_spans": [
                {
                    "start": 347,
                    "end": 351,
                    "text": "[85]",
                    "ref_id": "BIBREF84"
                },
                {
                    "start": 384,
                    "end": 388,
                    "text": "[86]",
                    "ref_id": "BIBREF85"
                },
                {
                    "start": 405,
                    "end": 409,
                    "text": "[87]",
                    "ref_id": "BIBREF86"
                }
            ],
            "ref_spans": [],
            "section": "Cons\u00e9quences virales"
        },
        {
            "text": "Par ailleurs, l'impact de l'utilisation des antagonistes de CCR5 sur le ph\u00e9notype viral a d\u00e9j\u00e0 \u00e9t\u00e9 analys\u00e9 in vitro et in vivo, mais les conclusions ne sont pas concordantes. Des \u00e9tudes in vitro ont sugg\u00e9r\u00e9 que l'utilisation de petites mol\u00e9cules antagonistes de CCR5 induisait l'\u00e9mergence de souches VIH-1 mut\u00e9es r\u00e9sistantes qui utilisaient CCR5 comme cor\u00e9cepteur m\u00eame en pr\u00e9sence de l'inhibiteur, mais incapables d'utiliser le cor\u00e9cepteur CXCR4 [88] [89] [90] . Inversement, l'utilisation d'une mol\u00e9cule d\u00e9riv\u00e9e de RANTES, antagoniste de CCR5, chez des souris hu-PBL-SCID infect\u00e9es par une souche R5, a induit l'apparition de souches X4 [91] . D'autres auteurs ont rapport\u00e9 que des macaques infect\u00e9s par deux souches R5 SIV et X4 SHIV ne pr\u00e9sentaient pas d'augmentation significative de leur charge virale en X4 apr\u00e8s traitement par inhibiteur de CCR5 [92] . Ainsi, il est difficile de conclure concernant l'effet de l'administration d'un antagoniste de CCR5 sur la commutation des souches virales, et le risque potentiel d'\u00e9mergence des souches X4 apr\u00e8s instauration d'un traitement par antagoniste CCR5 doit \u00eatre consid\u00e9r\u00e9 comme une possibilit\u00e9.",
            "cite_spans": [
                {
                    "start": 446,
                    "end": 450,
                    "text": "[88]",
                    "ref_id": "BIBREF87"
                },
                {
                    "start": 451,
                    "end": 455,
                    "text": "[89]",
                    "ref_id": "BIBREF88"
                },
                {
                    "start": 456,
                    "end": 460,
                    "text": "[90]",
                    "ref_id": "BIBREF89"
                },
                {
                    "start": 638,
                    "end": 642,
                    "text": "[91]",
                    "ref_id": "BIBREF90"
                },
                {
                    "start": 853,
                    "end": 857,
                    "text": "[92]",
                    "ref_id": "BIBREF91"
                }
            ],
            "ref_spans": [],
            "section": "Cons\u00e9quences virales"
        },
        {
            "text": "R\u00e9sistance aux antagonistes CCR5. Pour tout traitement antir\u00e9troviral, il existe un risque de r\u00e9sistance naturelle ou induite par le traitement. Ce risque provient du fait qu'il existe une certaine plasticit\u00e9 dans l'interaction entre gp120 et CCR5, ainsi que de la force variable de cette interaction.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cons\u00e9quences virales"
        },
        {
            "text": "En effet, ont \u00e9t\u00e9 identifi\u00e9es des souches R5 :",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cons\u00e9quences virales"
        },
        {
            "text": "qui gr\u00e2ce \u00e0 des mutations au sein de la boucle V3 de la gp120 deviennent tr\u00e8s affines (Fig. 4) pour CCR5 [10, 93, 94] , de sorte que la gp120 devient capable d'interagir avec le CCR5 m\u00eame en pr\u00e9sence de l'antagoniste [95] ; ou poss\u00e9dant des sites de liaison inhabituels (Fig. 4 ) [8, 9, [96] [97] [98] ; ou \u00e9tant peu inhib\u00e9es par les modifications des boucles extracellulaires de CCR5 [99] .",
            "cite_spans": [
                {
                    "start": 105,
                    "end": 109,
                    "text": "[10,",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 110,
                    "end": 113,
                    "text": "93,",
                    "ref_id": "BIBREF92"
                },
                {
                    "start": 114,
                    "end": 117,
                    "text": "94]",
                    "ref_id": "BIBREF93"
                },
                {
                    "start": 217,
                    "end": 221,
                    "text": "[95]",
                    "ref_id": "BIBREF94"
                },
                {
                    "start": 280,
                    "end": 283,
                    "text": "[8,",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 284,
                    "end": 286,
                    "text": "9,",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 287,
                    "end": 291,
                    "text": "[96]",
                    "ref_id": "BIBREF95"
                },
                {
                    "start": 292,
                    "end": 296,
                    "text": "[97]",
                    "ref_id": "BIBREF96"
                },
                {
                    "start": 297,
                    "end": 301,
                    "text": "[98]",
                    "ref_id": "BIBREF97"
                },
                {
                    "start": 385,
                    "end": 389,
                    "text": "[99]",
                    "ref_id": "BIBREF98"
                }
            ],
            "ref_spans": [
                {
                    "start": 86,
                    "end": 94,
                    "text": "(Fig. 4)",
                    "ref_id": "FIGREF2"
                },
                {
                    "start": 270,
                    "end": 277,
                    "text": "(Fig. 4",
                    "ref_id": "FIGREF2"
                }
            ],
            "section": "Cons\u00e9quences virales"
        },
        {
            "text": "De plus, Karlsson et al. ont d\u00e9montr\u00e9 qu'il existait au cours de l'infection par le VIH une \u00e9volution vers des souches R5 de moindre sensibilit\u00e9 \u00e0 l'inhibition par RANTES [100] . Toutes ces souches pourraient exister naturellement [101] et \u00e9merger lors de l'administration des antagonistes CCR5 [102] . Ce qui n'est pas encore \u00e9lucid\u00e9 est de savoir si ces souches auront un pouvoir de r\u00e9plication normal ou alt\u00e9r\u00e9 [103, 104] .",
            "cite_spans": [
                {
                    "start": 171,
                    "end": 176,
                    "text": "[100]",
                    "ref_id": "BIBREF99"
                },
                {
                    "start": 231,
                    "end": 236,
                    "text": "[101]",
                    "ref_id": "BIBREF100"
                },
                {
                    "start": 295,
                    "end": 300,
                    "text": "[102]",
                    "ref_id": "BIBREF101"
                },
                {
                    "start": 414,
                    "end": 419,
                    "text": "[103,",
                    "ref_id": "BIBREF102"
                },
                {
                    "start": 420,
                    "end": 424,
                    "text": "104]",
                    "ref_id": "BIBREF103"
                }
            ],
            "ref_spans": [],
            "section": "Cons\u00e9quences virales"
        },
        {
            "text": "Effets sur les r\u00e9ponses immunes sp\u00e9cifiques. Le chevauchement des sites de liaison de la gp120 et des chimiokines sur le CCR5 est responsable du fait que les antagonistes CCR5 bloquant le VIH-1 peuvent \u00e9galement emp\u00eacher la liaison des ligands physiologiques du CCR5. M\u00eame si cette \u00e9ventualit\u00e9 n'a pas de cons\u00e9quences n\u00e9fastes en conditions physiologiques, elle pourrait favoriser la survenue des maladies infectieuses o\u00f9 le cor\u00e9cepteur CCR5 joue un r\u00f4le important, par exemple dans le cas des infections opportunistes par le C. neoformans, le T. gondii ou l'Herpes virus. Ces consid\u00e9rations avantagent par cons\u00e9quent les antagonistes qui n'inhibent pas la fixation des chimiokines au CCR5. Inversement, ces m\u00eames antagonistes CCR5 inhibant la fixation des chimiokines pourraient \u00eatre b\u00e9n\u00e9fiques dans le cadre de pathologies dues \u00e0 la r\u00e9ponse immune antimicrobienne, ou bien dans le cadre de pathologies non infectieuses, telle l'ath\u00e9roscl\u00e9rose chez les patients infect\u00e9s par le VIH-1 dans lesquelles CCR5 joue un r\u00f4le d\u00e9l\u00e9t\u00e8re.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cons\u00e9quences immunologiques"
        },
        {
            "text": "Effets sur l'activation immune polyclonale et l'apoptose des cellules T. Si l'on consid\u00e8re le r\u00f4le du r\u00e9cepteur CCR5 dans l'activation des cellules T, ainsi que celui de l'activation T dans la progression de l'infection par le VIH-1 [105] , il est tentant de supposer que le CCR5 par l'interm\u00e9diaire de l'activation immunitaire cellulaire polyclonale pourrait \u00eatre impliqu\u00e9 dans la destruction des cellules T. En effet, de nombreuses \u00e9tudes plaident en faveur du r\u00f4le modulateur de CCR5 dans l'activation des cellules T et ainsi dans leur mort programm\u00e9e [106, 107] .",
            "cite_spans": [
                {
                    "start": 233,
                    "end": 238,
                    "text": "[105]",
                    "ref_id": "BIBREF104"
                },
                {
                    "start": 555,
                    "end": 560,
                    "text": "[106,",
                    "ref_id": "BIBREF105"
                },
                {
                    "start": 561,
                    "end": 565,
                    "text": "107]",
                    "ref_id": "BIBREF106"
                }
            ],
            "ref_spans": [],
            "section": "Cons\u00e9quences immunologiques"
        },
        {
            "text": "Deux travaux en particulier vont dans le sens de cette hypoth\u00e8se. D'une part, l'\u00e9quipe d'Ahuja a d\u00e9montr\u00e9 qu'il existait un rapport entre l'\u00e9volutivit\u00e9 de la maladie et la g\u00e9n\u00e9tique des patients (g\u00e9notype CCR5 et nombre des copies du g\u00e8ne CCL3-L1) ind\u00e9pendamment du niveau de r\u00e9plication virale [108] . Par cons\u00e9quent, on pourrait imaginer que l'axe form\u00e9 par CCR5 et ses ligands pourrait \u00eatre impliqu\u00e9 dans un m\u00e9canisme de destruction cellulaire ne faisant pas intervenir le virus.",
            "cite_spans": [
                {
                    "start": 295,
                    "end": 300,
                    "text": "[108]",
                    "ref_id": "BIBREF107"
                }
            ],
            "ref_spans": [],
            "section": "Cons\u00e9quences immunologiques"
        },
        {
            "text": "D'autre part, les travaux de Pandrea et al. chez les primates concluent que les primates infect\u00e9s par le virus SIV qui \u00e9voluent vers le stade SIDA ont une forte expression de CCR5 \u00e0 la surface de leurs cellules T CD4+, tandis que ceux qui ne poss\u00e8dent pas une forte activation immunitaire et qui ne progressent pas malgr\u00e9 une forte vir\u00e9mie, sous-expriment CCR5 [109] .",
            "cite_spans": [
                {
                    "start": 361,
                    "end": 366,
                    "text": "[109]",
                    "ref_id": "BIBREF108"
                }
            ],
            "ref_spans": [],
            "section": "Cons\u00e9quences immunologiques"
        },
        {
            "text": "De plus, l'hypoth\u00e8se d'une responsabilit\u00e9 immunologique de CCR5 dans la destruction des cellules T CD4+ ind\u00e9pendamment de sa responsabilit\u00e9 en tant que cor\u00e9cepteur, pourrait expliquer le fait que dans les \u00e9tudes cliniques r\u00e9centes, les sujets infect\u00e9s par le VIH-1 et trait\u00e9s par des antagonistes du CCR5 pr\u00e9sentent une augmentation inhabituelle de leur nombre de cellules T CD4+ par rapport aux sujets non trait\u00e9s par anti-CCR5. En effet, une m\u00e9ta-analyse des \u00e9tudes cliniques de phase II/III chez des patients pr\u00e9trait\u00e9s a prouv\u00e9 que cette restauration immunologique \u00e9tait sup\u00e9rieure sous anti-CCR5 [110] . Il est \u00e0 souligner que, dans ces m\u00eames \u00e9tudes, l'augmentation de cellules T CD4+ est ind\u00e9pendante de l'efficacit\u00e9 virologique [111] , concerne \u00e9galement les sujets infect\u00e9s par des souches R5/X4 et X4 (+30 et +56 cellules T CD4+/ml respectivement dans les groupes d'une ou deux prises quotidiennes de MVC des \u00e9tudes MOTIVATE) [112, 113] un ou deux ans de traitement antir\u00e9troviral intensif. En France, l'\u00e9tude Marimuno est une \u00e9tude pilote \u00e9valuant le b\u00e9n\u00e9fice immunologique d'une intensification de 24 semaines par MVC (Celsentri 1 ) chez des patients sous traitement antir\u00e9troviral stable (! 24 mois) et efficace (CV < 50 copies/ml) mais avec restauration immunologique incompl\u00e8te (CD4 < 350 cellules/mm 3 ).",
            "cite_spans": [
                {
                    "start": 601,
                    "end": 606,
                    "text": "[110]",
                    "ref_id": "BIBREF109"
                },
                {
                    "start": 735,
                    "end": 740,
                    "text": "[111]",
                    "ref_id": "BIBREF110"
                },
                {
                    "start": 935,
                    "end": 940,
                    "text": "[112,",
                    "ref_id": "BIBREF111"
                },
                {
                    "start": 941,
                    "end": 945,
                    "text": "113]",
                    "ref_id": "BIBREF112"
                }
            ],
            "ref_spans": [],
            "section": "Cons\u00e9quences immunologiques"
        },
        {
            "text": "Enfin, si les antagonistes de CCR5 sont capables de diminuer l'activation immunitaire globale, ils pourraient \u00e9galement \u00eatre indiqu\u00e9s dans le cas du syndrome inflammatoire de restauration immunitaire (IRIS) o\u00f9 cette activation peut avoir des cons\u00e9quences graves.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cons\u00e9quences immunologiques"
        },
        {
            "text": "Seules trois mol\u00e9cules antagonistes du CCR5 ont fait l'objet d'essais cliniques randomis\u00e9s.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Mol\u00e9cules antagonistes du CCR5 en d\u00e9veloppement clinique avanc\u00e9"
        },
        {
            "text": "Malgr\u00e9 une activit\u00e9 antir\u00e9trovirale similaire in vitro \u00e0 celle du vicriviroc (VCV) et du maraviroc (MVC) [114] , le laboratoire GlaxoSmithKline a interrompu tous les essais ainsi que le d\u00e9veloppement de cette mol\u00e9cule en 2005, devant la constatation de quatre cas de toxicit\u00e9 h\u00e9patique parfois fatale [115] . L'\u00e9tude de phase IIb EPIC chez des patients na\u00effs de tout traitement antir\u00e9troviral et infect\u00e9s par une souche R5 ou duale/mixte a rapport\u00e9 une activit\u00e9 antir\u00e9trovirale du bras aplaviroc inf\u00e9rieure \u00e0 celle du bras t\u00e9moin lamivudine/zidovudine (chacun en association avec lopinavir/ritonavir), avec une grande variabilit\u00e9 interindividuelle de r\u00e9ponse virologique [116] .",
            "cite_spans": [
                {
                    "start": 105,
                    "end": 110,
                    "text": "[114]",
                    "ref_id": "BIBREF113"
                },
                {
                    "start": 301,
                    "end": 306,
                    "text": "[115]",
                    "ref_id": "BIBREF114"
                },
                {
                    "start": 671,
                    "end": 676,
                    "text": "[116]",
                    "ref_id": "BIBREF115"
                }
            ],
            "ref_spans": [],
            "section": "Aplaviroc"
        },
        {
            "text": "Le VCV (anciennement d\u00e9nomm\u00e9 SCH417690 ou SCH-D) est une petite mol\u00e9cule antagoniste du CCR5, \u00e0 biodisponibilit\u00e9 orale, efficace \u00e0 des concentrations nanomolaires [117] . Il est m\u00e9tabolis\u00e9 par le cytochrome CYP3A4 et ses concentrations plasmatiques se trouvent augment\u00e9es d'un facteur allant de 2 \u00e0 6 s'il est coadministr\u00e9 avec 100 mg de ritonavir, ce qui lui conf\u00e8re une demi-vie plasmatique de plus de 24 heures, permettant une seule prise quotidienne [118] . Les \u00e9tudes pr\u00e9cliniques ont objectiv\u00e9 des crises convulsives chez des animaux recevant des doses \u00e9lev\u00e9es, cependant aucun effet secondaire neurologique central n'a \u00e9t\u00e9 observ\u00e9 dans les \u00e9tudes cliniques \u00e0 ce jour. La premi\u00e8re \u00e9tude randomis\u00e9e prouvant l'efficacit\u00e9 clinique du VCV a \u00e9t\u00e9 effectu\u00e9e chez des patients ayant un tropisme R5, na\u00effs ou n'ayant pas re\u00e7u de traitement antir\u00e9troviral pendant au moins huit semaines [119] . Le VCV a \u00e9t\u00e9 administr\u00e9 en monoth\u00e9rapie de 14 jours versus placebo, avec des doses de 10, 25 ou 50 mg deux fois par jour, ce qui conf\u00e9rait une diminution de la charge virale plasmatique d'au moins un log chez respectivement 45, 77 et 82 % des patients. La tol\u00e9rance des groupes sous VCV ou placebo a \u00e9t\u00e9 similaire.",
            "cite_spans": [
                {
                    "start": 163,
                    "end": 168,
                    "text": "[117]",
                    "ref_id": "BIBREF116"
                },
                {
                    "start": 454,
                    "end": 459,
                    "text": "[118]",
                    "ref_id": "BIBREF117"
                },
                {
                    "start": 884,
                    "end": 889,
                    "text": "[119]",
                    "ref_id": "BIBREF118"
                }
            ],
            "ref_spans": [],
            "section": "Vicriviroc (VCV)"
        },
        {
            "text": "Une \u00e9tude randomis\u00e9e de phase IIb chez des patients infect\u00e9s par le VIH-1 et na\u00effs de tout traitement antir\u00e9troviral a \u00e9t\u00e9 interrompue avant la dur\u00e9e pr\u00e9vue de 48 semaines \u00e0 cause des taux \u00e9lev\u00e9s d'\u00e9chec virologique dans deux bras de VCV. Elle compara\u00eet trois posologies de VCV \u00e0 une prise quotidienne (QD) (25, 50 ou 75 mg) entre elles et avec le bras t\u00e9moin d'efavirenz (EFV) (les patients ont re\u00e7u le VCV ou le placebo en monoth\u00e9rapie pendant 14 jours, puis le VCV ou l'EFV combin\u00e9s \u00e0 zidovudine-lamivudine dans une association ZDV/3TC \u00e0 posologie fixe) (Tableau 2) [120] . Au moment de l'arr\u00eat de l'\u00e9tude, seul le bras sous 75 mg de VCV donnait un taux d'\u00e9chec virologique qui n'\u00e9tait pas statistiquement diff\u00e9rent par rapport au bras t\u00e9moin d'EFV.",
            "cite_spans": [
                {
                    "start": 569,
                    "end": 574,
                    "text": "[120]",
                    "ref_id": "BIBREF119"
                }
            ],
            "ref_spans": [],
            "section": "Vicriviroc (VCV)"
        },
        {
            "text": "Malgr\u00e9 le fait que dans cette \u00e9tude le m\u00e9canisme pr\u00e9cis d'\u00e9chec virologique n'ait pas \u00e9t\u00e9 identifi\u00e9, le taux \u00e9lev\u00e9 d'\u00e9mergence de la mutation M184 V chez tous les patients en \u00e9chec virologique \u00e9voque une inhibition inad\u00e9quate de la r\u00e9plication virologique par le VCV aux conditions d'administration utilis\u00e9es pendant l'\u00e9tude. Par ailleurs, l'absence de plateau dans la courbe dose-r\u00e9ponse lors de l'analyse posthoc, ainsi que la grande variabilit\u00e9 de la concentration inhibitrice 50 (IC 50 ) sugg\u00e8rent que des doses plus \u00e9lev\u00e9es de VCV sont n\u00e9cessaires afin d'optimiser la suppression Tableau 2 R\u00e9sultats de l'\u00e9tude IIb chez les patients na\u00effs.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vicriviroc (VCV)"
        },
        {
            "text": "Outcomes of the phase IIb study in treatment-naive subjects. [121] . M\u00eame si cette analyse sugg\u00e8re de meilleurs taux de r\u00e9ponse si les souches ont un tropisme R5 inchang\u00e9 aux visites de s\u00e9lection et d'inclusion, son impact sur la r\u00e9ponse virologique de 24 semaines para\u00eet minime. Concernant les effets ind\u00e9sirables, huit cas de pathologie tumorale maligne ont \u00e9t\u00e9 observ\u00e9s sous VCV versus deux cas sous placebo avec un lien de causalit\u00e9 qui a finalement \u00e9t\u00e9 infirm\u00e9 par l'\u00e9tude Vicriviroc in Combination Treatment with Optimized ART Regimen (VICTOR-E1) [122] .",
            "cite_spans": [
                {
                    "start": 61,
                    "end": 66,
                    "text": "[121]",
                    "ref_id": "BIBREF120"
                },
                {
                    "start": 553,
                    "end": 558,
                    "text": "[122]",
                    "ref_id": "BIBREF121"
                }
            ],
            "ref_spans": [],
            "section": "Vicriviroc (VCV)"
        },
        {
            "text": "L'\u00e9tude VICTOR-E1 [118] est une \u00e9tude randomis\u00e9e, en double insu chez des patients pr\u00e9trait\u00e9s avec les trois classes d'antir\u00e9troviraux, poss\u00e9dant au moins une r\u00e9sistance document\u00e9e aux inhibiteurs de prot\u00e9ase et aux inhibiteurs nucl\u00e9osidiques de la transcriptase inverse (INTI). Elle a \u00e9valu\u00e9 l'efficacit\u00e9 immunovirologique de 20 ou 30 mg de VCV par jour versus placebo, en association dans les trois bras \u00e0 un traitement optimis\u00e9. La diminution de l'ARN VIH plasmatique observ\u00e9e sous VCV \u00e9tait en moyenne de 1,75 log versus 0,79 log sous placebo, ind\u00e9pendamment du nombre des mol\u00e9cules actives inclues dans le traitement optimis\u00e9 (Tableau 4). Elle a \u00e9galement d\u00e9montr\u00e9 la sup\u00e9riorit\u00e9 de la dose de 30 mg de VCV chez les patients avanc\u00e9s (charge virale plasmatique sup\u00e9rieure \u00e0 100 000 copies/ml) ou quand le traitement optimis\u00e9 ne comprenait aucune ou seulement une mol\u00e9cule active. Une augmentation significative du nombre des cellules T CD4+ a \u00e9t\u00e9 d\u00e9tect\u00e9e uniquement dans le bras de 20 mg de VCV. La tol\u00e9rance clinicobiologique a \u00e9t\u00e9 comparable dans les trois bras et aucune pathologie tumorale maligne n'a \u00e9t\u00e9 rapport\u00e9e.",
            "cite_spans": [
                {
                    "start": 18,
                    "end": 23,
                    "text": "[118]",
                    "ref_id": "BIBREF117"
                }
            ],
            "ref_spans": [],
            "section": "Vicriviroc (VCV)"
        },
        {
            "text": "Deux larges \u00e9tudes de phase III, VICTOR-E3 et VICTOR-E4, sont actuellement en cours, comparant deux bras : le VCV \u00e0 30 mg QD versus placebo, en association avec un traitement optimis\u00e9 chez des patients pr\u00e9trait\u00e9s. [123] . Son m\u00e9canisme d'action passe par une liaison r\u00e9versible au cor\u00e9cepteur CCR5 [124] , \u00e0 l'origine d'un changement conformationnel de ce dernier, ce qui emp\u00eache l'interaction de la gp120 avec la boucle V3. Sa demi-vie plasmatique est de 13,2 heures et la mol\u00e9cule est m\u00e9tabolis\u00e9e par le cytochrome CYP3A4 et le substrat P-gp, sans pourtant induire ou inhiber les enzymes de ce cytochrome [125] . Des \u00e9tudes de phase II chez des patients asymptomatiques ayant des souches \u00e0 tropisme R5 ont \u00e9t\u00e9 r\u00e9alis\u00e9es, avec administration de dix jours de MVC en monoth\u00e9rapie, et suivi jusqu'\u00e0 j40 ; la r\u00e9duction de la charge virale plasmatique \u00e9tait d'au moins 1,35 log \u00e0 partir d'une dose journali\u00e8re de 200 mg. Les donn\u00e9es de pharmacocin\u00e9tique ont sugg\u00e9r\u00e9 que l'alimentation r\u00e9duit la concentration maximale ainsi que l'aire sous la courbe [126] .",
            "cite_spans": [
                {
                    "start": 214,
                    "end": 219,
                    "text": "[123]",
                    "ref_id": "BIBREF122"
                },
                {
                    "start": 298,
                    "end": 303,
                    "text": "[124]",
                    "ref_id": null
                },
                {
                    "start": 607,
                    "end": 612,
                    "text": "[125]",
                    "ref_id": "BIBREF124"
                },
                {
                    "start": 1046,
                    "end": 1051,
                    "text": "[126]",
                    "ref_id": "BIBREF125"
                }
            ],
            "ref_spans": [],
            "section": "Vicriviroc (VCV)"
        },
        {
            "text": "L'efficacit\u00e9 et la bonne tol\u00e9rance du MVC ont \u00e9t\u00e9 d\u00e9montr\u00e9es chez des patients pr\u00e9trait\u00e9s, en \u00e9chec virologique et infect\u00e9s par des souches R5, dans les \u00e9tudes cliniques randomis\u00e9es et en double insu Motivate-1 et Motivate-2 de phase IIb/III (Tableau 5) [127, 128] comparant trois bras : placebo, MVC 150 mg en une ou deux prises quotidiennes (QID), chacun en addition \u00e0 un traitement optimis\u00e9 (randomisation selon un sch\u00e9ma 1 : 2 : 2). L'analyse \u00ab pool\u00e9e \u00bb des r\u00e9sultats \u00e0 48 semaines de traitement ont montr\u00e9 une r\u00e9ponse virologique significativement sup\u00e9rieure aux bras avec MVC, aussi bien en termes de r\u00e9duction moyenne de la charge virale plasmatique que de pourcentage des patients atteignant l'ind\u00e9tectabilit\u00e9 de l'ARN VIH-1 (Tableau 5). Cette r\u00e9ponse \u00e9tait d'autant plus prononc\u00e9e que les patients avaient une charge virale de base inf\u00e9rieure \u00e0 100 000 copies/ml ou un chiffre de cellules T CD4+ \u00e9lev\u00e9 [129] ; de m\u00eame, le pourcentage obtenu d'ind\u00e9tectabilit\u00e9 au seuil de 50 copies/ml \u00e9tait influenc\u00e9 par le nombre des mol\u00e9cules actives dans le traitement optimis\u00e9 associ\u00e9 [125, 129] . En effet : on observait une am\u00e9lioration des r\u00e9sultats virologiques avec un nombre croissant des mol\u00e9cules actives ; une diff\u00e9rence apparaissait entre les deux bras de MVC en absence de mol\u00e9cule active (en faveur de la double prise quotidienne) ; en pr\u00e9sence d'au moins trois mol\u00e9cules actives le taux de succ\u00e8s paraissait similaire dans les trois bras.",
            "cite_spans": [
                {
                    "start": 254,
                    "end": 259,
                    "text": "[127,",
                    "ref_id": "BIBREF126"
                },
                {
                    "start": 260,
                    "end": 264,
                    "text": "128]",
                    "ref_id": "BIBREF127"
                },
                {
                    "start": 911,
                    "end": 916,
                    "text": "[129]",
                    "ref_id": "BIBREF128"
                },
                {
                    "start": 1081,
                    "end": 1086,
                    "text": "[125,",
                    "ref_id": "BIBREF124"
                },
                {
                    "start": 1087,
                    "end": 1091,
                    "text": "129]",
                    "ref_id": "BIBREF128"
                }
            ],
            "ref_spans": [],
            "section": "Vicriviroc (VCV)"
        },
        {
            "text": "La r\u00e9ponse immunologique en termes de gain de cellules T CD4+ \u00e9tait \u00e9galement significativement sup\u00e9rieure dans les bras de MVC (m\u00eame pour les patients en \u00e9chec virologique) comparativement au placebo, et chez les patients avec un tropisme R5 conserv\u00e9 \u00e0 l'\u00e9chec ; le gain en cellules T CD4+ \u00e9tait pourtant moindre chez les patients ayant une r\u00e9sistance document\u00e9e aux trois classes antir\u00e9trovirales classiques (+108 cellules/ml versus +150 cellules/ml). D'ailleurs, ces derniers \u00e9taient \u00e9galement plus susceptibles \u00e0 l'\u00e9chec virologique (45,6 % versus 37,6 %) [125] . Le profil de tol\u00e9rance \u00e9tait comparable dans les bras avec ou sans MVC [129] , notamment sans diff\u00e9rence significative du nombre d'interruptions th\u00e9rapeutiques dues aux effets secondaires, de l'h\u00e9patotoxicit\u00e9 chez les patients co-infect\u00e9s avec le virus de l'h\u00e9patite B et C [130] , ou du taux des pathologies tumorales malignes associ\u00e9es ou non au VIH [129] . Lors de l'analyse des sous-groupes relativement aux modifications de tropisme, on a constat\u00e9 que 8 % des 1042 patients ayant un tropisme R5 \u00e0 la visite de s\u00e9lection avaient un tropisme DM \u00e0 la visite d'inclusion [127] . Parmi les patients en \u00e9chec th\u00e9rapeutique avec un tropisme initial R5, 57 % avaient un tropisme X4/DM \u00e0 l'\u00e9chec, dont la majorit\u00e9 avait re\u00e7u du MVC.",
            "cite_spans": [
                {
                    "start": 560,
                    "end": 565,
                    "text": "[125]",
                    "ref_id": "BIBREF124"
                },
                {
                    "start": 639,
                    "end": 644,
                    "text": "[129]",
                    "ref_id": "BIBREF128"
                },
                {
                    "start": 842,
                    "end": 847,
                    "text": "[130]",
                    "ref_id": "BIBREF129"
                },
                {
                    "start": 920,
                    "end": 925,
                    "text": "[129]",
                    "ref_id": "BIBREF128"
                },
                {
                    "start": 1140,
                    "end": 1145,
                    "text": "[127]",
                    "ref_id": "BIBREF126"
                }
            ],
            "ref_spans": [],
            "section": "Vicriviroc (VCV)"
        },
        {
            "text": "Plus sp\u00e9cifiquement, van der Ryst et Westby [113] [133] , qui a \u00e9valu\u00e9 le r\u00f4le du MVC (300 mg une ou deux fois par jour) versus l'EFV, chacun en association avec le combivir (CBV), chez 721 patients na\u00effs porteurs de souches de tropisme R5. \u00c0 48 semaines, et apr\u00e8s r\u00e9analyse \u00e0 l'aide du test ph\u00e9noty-pique Enhanced Sensitivity Trofile 1 Assay (ESTA) qui a reclass\u00e9 15 % des souches R5 de la visite d'inclusion (tropisme effectu\u00e9 \u00e0 l'aide de l'essai Trofile 1 standard) en souches R5/ X4, il a \u00e9t\u00e9 d\u00e9montr\u00e9 la non-inf\u00e9riorit\u00e9 du MVC par rapport \u00e0 l'EFV, avec un niveau de non-inf\u00e9riorit\u00e9 pr\u00e9d\u00e9fini \u00e0 10 % [134] . En effet, la proportion des patients dont la CV \u00e9tait ind\u00e9tectable au seuil de 400 copies/ml \u00e9tait de 73,3 % dans le bras MVC versus 72,3 % dans le bras EFV (diff\u00e9rence de 0,6 avec la limite inf\u00e9rieure de l'IC 97,5 % -6,4, mais pourtant avec un int\u00e9r\u00eat purement descriptif sachant qu'il ne s'agit pas de l'analyse primaire), tandis qu'au seuil de 50 copies/ml, les taux \u00e9taient de 68,5 % et de 68,3 % respectivement (diff\u00e9rence de \u00c00,2 avec limite de l'IC \u00e0 \u00c07,4). La restauration immunologique \u00e9tait meilleure dans le bras MVC comparativement au bras EFV (respectivement +174 cellules/mm 3 versus +144 cellules/mm 3 , diff\u00e9rence de 30 avec IC 95 % [10,51]) [135] . Enfin, plus de patients dans le bras MVC ont arr\u00eat\u00e9 le traitement \u00e0 cause d'un manque d'efficacit\u00e9 (9,3 % versus 4 %), tandis que plus de patients du bras EFV ont pr\u00e9sent\u00e9 des pathologies malignes ou ont arr\u00eat\u00e9 le traitement \u00e0 cause d'effets ind\u00e9sirables de grade 3 ou 4 (14,2 % versus 4,2 %).",
            "cite_spans": [
                {
                    "start": 44,
                    "end": 49,
                    "text": "[113]",
                    "ref_id": "BIBREF112"
                },
                {
                    "start": 50,
                    "end": 55,
                    "text": "[133]",
                    "ref_id": "BIBREF132"
                },
                {
                    "start": 604,
                    "end": 609,
                    "text": "[134]",
                    "ref_id": "BIBREF133"
                },
                {
                    "start": 1270,
                    "end": 1275,
                    "text": "[135]",
                    "ref_id": "BIBREF135"
                }
            ],
            "ref_spans": [],
            "section": "Vicriviroc (VCV)"
        },
        {
            "text": "Diverses \u00e9tudes sont en cours concernant le d\u00e9veloppement d'approches qui visent \u00e0 diminuer la fonctionnalit\u00e9 de CCR5 en tant que cor\u00e9cepteur du VIH.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Alternatives des antagonistes CCR5"
        },
        {
            "text": "En ce qui concerne les approches extracellulaires, les travaux actuels portent essentiellement sur : l'utilisation d'anticorps anti-CCR5 (PRO140, HGS 004, HGS 101) [111, 136, 137] ou d'autres petites mol\u00e9cules inhibant CCR5 (INCB009471, TAK-779 ou 652) [138, 139] ; la recherche de situations biologiques ou m\u00e9dicamenteuses pouvant induire l'augmentation plasmatique des chimiokines liant CCR5 (dans la mesure o\u00f9 ces derni\u00e8res soit induisent l'internalisation des mol\u00e9cules CCR5, soit sont en comp\u00e9tition avec les virions pour la liaison au CCR5) [140] ; la recherche d'autres RCPG qui pourraient interagir avec CCR5 (h\u00e9t\u00e9rodim\u00e9risation, internalisation et/ou h\u00e9t\u00e9rod\u00e9sensibilisation) entra\u00eenant ainsi une interf\u00e9rence avec la fixation de la particule virale sur le CCR5 [141] . Tableau 6 Efficacit\u00e9 \u00e0 24 semaines du MVC chez des patients infect\u00e9s avec une souche D/M du VIH-1 au moment de la visite de s\u00e9lection. Efficacy of maraviroc at 24 weeks in patients infected with dual-or mixed-tropic human immunodeficiency virus type 1 (HIV-1) at screening.",
            "cite_spans": [
                {
                    "start": 164,
                    "end": 169,
                    "text": "[111,",
                    "ref_id": "BIBREF110"
                },
                {
                    "start": 170,
                    "end": 174,
                    "text": "136,",
                    "ref_id": "BIBREF136"
                },
                {
                    "start": 175,
                    "end": 179,
                    "text": "137]",
                    "ref_id": "BIBREF137"
                },
                {
                    "start": 253,
                    "end": 258,
                    "text": "[138,",
                    "ref_id": "BIBREF138"
                },
                {
                    "start": 259,
                    "end": 263,
                    "text": "139]",
                    "ref_id": "BIBREF139"
                },
                {
                    "start": 547,
                    "end": 552,
                    "text": "[140]",
                    "ref_id": "BIBREF140"
                },
                {
                    "start": 771,
                    "end": 776,
                    "text": "[141]",
                    "ref_id": "BIBREF141"
                }
            ],
            "ref_spans": [],
            "section": "Alternatives des antagonistes CCR5"
        },
        {
            "text": "Placebo (n = 58) Maraviroc QD (n = 57) Maraviroc BID (n = 52)",
            "cite_spans": [
                {
                    "start": 13,
                    "end": 16,
                    "text": "58)",
                    "ref_id": "BIBREF57"
                }
            ],
            "ref_spans": [],
            "section": "Bras th\u00e9rapeutique"
        },
        {
            "text": "Variation moyenne de la CV \u00e0 partir des valeurs \u00e0 l'inclusion (log 10 copies/ml) \u00c00,97 \u00c00,91 ( p = 0,83) \u00c01,20 ( p = 0,38)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Bras th\u00e9rapeutique"
        },
        {
            "text": "CV plasmatique < 50 copies/ml (% des patients) 16 21 27 Variation moyenne des cellules T CD4+/ml Sur le total des 167 patients +36 +60 ( p = 0,06) +62 ( p = 0,04) Chez les patients interrompant l'\u00e9tude pour \u00e9chec th\u00e9rapeutique En particulier, l'anticorps PRO140 (anticorps inhibant l'attachement du VIH sans inhiber les fonctions naturelles du CCR5) a \u00e9t\u00e9 \u00e9valu\u00e9 lors d'une \u00e9tude randomis\u00e9e, en double insu versus placebo, chez des patients pr\u00e9trait\u00e9s, en interruption th\u00e9rapeutique depuis 12 semaines, ayant plus de 300 cellules T CD4+/mm 3 et porteurs de souches virales de tropisme R5 [142] . Quarante-quatre patients ont ainsi \u00e9t\u00e9 randomis\u00e9s en quatre bras (monoth\u00e9rapie de PRO140 \u00e0 trois posologies diff\u00e9rentes en sous-cutan\u00e9 versus placebo) dont l'\u00e9volution virologique est repr\u00e9sent\u00e9e cidessous (Tableau 7). La tol\u00e9rance semblait satisfaisante, y compris cutan\u00e9e aux points d'injection.",
            "cite_spans": [
                {
                    "start": 50,
                    "end": 52,
                    "text": "21",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 588,
                    "end": 593,
                    "text": "[142]",
                    "ref_id": "BIBREF142"
                }
            ],
            "ref_spans": [],
            "section": "Bras th\u00e9rapeutique"
        },
        {
            "text": "D'un point de vue intracellulaire :",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Bras th\u00e9rapeutique"
        },
        {
            "text": "des mol\u00e9cules inhibant l'expression du g\u00e8ne CCR5 (rapamycine, prostaglandine E2, statines, thalidomide ou antioxydants) sont en cours d'\u00e9tude [143] [144] [145] [146] [147] ; le transfert de g\u00e8nes interf\u00e9rant avec l'expression de CCR5 (plasmide codant pour l'anticorps intracellulaire ST6, vecteur lentiviral exprimant des micro ARN anti-CCR5) semble prometteur in vitro mais d'application in vivo encore probl\u00e9matique [148, 149] .",
            "cite_spans": [
                {
                    "start": 142,
                    "end": 147,
                    "text": "[143]",
                    "ref_id": "BIBREF143"
                },
                {
                    "start": 148,
                    "end": 153,
                    "text": "[144]",
                    "ref_id": "BIBREF144"
                },
                {
                    "start": 154,
                    "end": 159,
                    "text": "[145]",
                    "ref_id": "BIBREF145"
                },
                {
                    "start": 160,
                    "end": 165,
                    "text": "[146]",
                    "ref_id": "BIBREF146"
                },
                {
                    "start": 166,
                    "end": 171,
                    "text": "[147]",
                    "ref_id": "BIBREF147"
                },
                {
                    "start": 418,
                    "end": 423,
                    "text": "[148,",
                    "ref_id": "BIBREF148"
                },
                {
                    "start": 424,
                    "end": 428,
                    "text": "149]",
                    "ref_id": "BIBREF149"
                }
            ],
            "ref_spans": [],
            "section": "Bras th\u00e9rapeutique"
        },
        {
            "text": "L'utilisation de CCR5 en tant que nouvelle cible de la th\u00e9rapeutique antir\u00e9trovirale semble prometteuse. Les antagonistes de CCR5 bloquent le cycle de r\u00e9plication du VIH-1 \u00e0 un stade tr\u00e8s pr\u00e9coce. L'efficacit\u00e9 virologique et la bonne tol\u00e9rance des anti-CCR5 sont confirm\u00e9es par toutes les \u00e9tudes cliniques r\u00e9centes, qui ne d\u00e9montrent par ailleurs pas d'effets toxiques ou de r\u00e9sistance crois\u00e9e avec les autres classes th\u00e9rapeutiques. Cependant, plusieurs points restent encore \u00e0 \u00e9claircir comme la tol\u00e9rance \u00e0 long terme, le risque d'induction de la commutation R5-X4, le risque de diminuer certaines r\u00e9ponses immunitaires sp\u00e9cifiques, l'impact clinique d'un tropisme \u00e9ventuellement discordant entre le plasma et les autres compartiments de l'organisme, ainsi que les interactions potentielles avec les autres antir\u00e9troviraux. Leur profil conf\u00e9rant une restauration immunologique sup\u00e9rieure suscite l'\u00e9valuation des antagonistes CCR5 chez les patients en immunod\u00e9pression s\u00e9v\u00e8re ou ayant une r\u00e9ponse immunovirologique dissoci\u00e9e. En dehors de leur r\u00f4le en pathologie infectieuse, les antagonistes CCR5 pourraient avoir des indications d'utilisation dans les pathologies o\u00f9 le r\u00e9cepteur CCR5 est impliqu\u00e9, comme le rejet des greffes et les maladies auto-immunes. M\u00e9diane D \u00e0 j22 (log 10 ) +0,21 \u00c00,75 \u00c01,20 \u00c01,51",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusion"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Alkhatib",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Science",
            "volume": "272",
            "issn": "5270",
            "pages": "1955--1963",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Choe",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Cell",
            "volume": "85",
            "issn": "7",
            "pages": "1135--1183",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Identification of a major co-receptor for primary isolates of HIV-1",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Nature",
            "volume": "381",
            "issn": "6584",
            "pages": "661--667",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Doranz",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Cell",
            "volume": "85",
            "issn": "7",
            "pages": "1149--58",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Dragic",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Nature",
            "volume": "381",
            "issn": "6584",
            "pages": "667--73",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Feng",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Science",
            "volume": "272",
            "issn": "5263",
            "pages": "872--879",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Molecular cloning and functional expression of a new human CC-chemokine receptor gene",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Samson",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Biochemistry",
            "volume": "35",
            "issn": "11",
            "pages": "3362--3369",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage-and dualtropic isolates of human immunodeficiency virus type 1",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "E"
                    ],
                    "last": "Rabut",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "J Virol",
            "volume": "72",
            "issn": "4",
            "pages": "3464--3472",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Thompson",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "G"
                    ],
                    "last": "Cormier",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Dragic",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "J Virol",
            "volume": "76",
            "issn": "6",
            "pages": "3059--64",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "E"
                    ],
                    "last": "Kuhmann",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "J Virol",
            "volume": "74",
            "issn": "15",
            "pages": "7005--7020",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Dean",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Multicenter AIDS Cohort Study",
            "volume": "273",
            "issn": "5283",
            "pages": "1856--62",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Cell",
            "volume": "86",
            "issn": "3",
            "pages": "367--77",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "HIV-1 entry inhibitors: evading the issue",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "L"
                    ],
                    "last": "Michael",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Moore",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Nat Med",
            "volume": "5",
            "issn": "7",
            "pages": "740--742",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals",
            "authors": [
                {
                    "first": "Z",
                    "middle": [
                        "L"
                    ],
                    "last": "Brumme",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Infect Dis",
            "volume": "192",
            "issn": "3",
            "pages": "466--74",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "D"
                    ],
                    "last": "Richman",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Bozzette",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "J Infect Dis",
            "volume": "169",
            "issn": "5",
            "pages": "968--74",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Waters",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Clin Infect Dis",
            "volume": "46",
            "issn": "10",
            "pages": "1617--1640",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Weiser",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "AIDS",
            "volume": "22",
            "issn": "4",
            "pages": "469--79",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "C"
                    ],
                    "last": "Bou-Habib",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "J Virol",
            "volume": "68",
            "issn": "9",
            "pages": "6006--6019",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Harouse",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Proc Natl Acad Sci",
            "volume": "100",
            "issn": "",
            "pages": "10977--82",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Constitutive cell surface association between CD4 and CCR5",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Proc Natl Acad Sci U S A",
            "volume": "96",
            "issn": "13",
            "pages": "7496--501",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Doranz",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "S"
                    ],
                    "last": "Baik",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "W"
                    ],
                    "last": "Doms",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "J Virol",
            "volume": "73",
            "issn": "12",
            "pages": "10346--58",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Infection of human tonsil histocultures: a model for HIV pathogenesis",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Glushakova",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "Nat Med",
            "volume": "1",
            "issn": "12",
            "pages": "1320--1322",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "C"
                    ],
                    "last": "Bleul",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "Proc Natl Acad Sci U S A",
            "volume": "94",
            "issn": "5",
            "pages": "1925--1955",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Proc Natl Acad Sci",
            "volume": "96",
            "issn": "9",
            "pages": "5215--5235",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Cellular localization of the chemokine receptor CCR5, Correlation to cellular targets of HIV-1 infection",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Rottman",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "Am J Pathol",
            "volume": "151",
            "issn": "5",
            "pages": "1341--51",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Reynes",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "J Infect Dis",
            "volume": "181",
            "issn": "3",
            "pages": "927--959",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Genetic acceleration of AIDS progression by a promoter variant of CCR5",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "P"
                    ],
                    "last": "Martin",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "Science",
            "volume": "282",
            "issn": "5395",
            "pages": "1907--1918",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "CCR5 promoter polymorphism and HIV-1 disease progression, Multicenter AIDS Cohort Study (MACS)",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "H"
                    ],
                    "last": "Mcdermott",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "Lancet",
            "volume": "352",
            "issn": "9131",
            "pages": "866--70",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mummidi",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "Nat Med",
            "volume": "4",
            "issn": "7",
            "pages": "786--93",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5",
            "authors": [
                {
                    "first": "Y",
                    "middle": [
                        "L"
                    ],
                    "last": "Lin",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "AIDS",
            "volume": "22",
            "issn": "3",
            "pages": "430--432",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Endocytosis and recycling of the HIV coreceptor CCR5",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Signoret",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "J Cell Biol",
            "volume": "151",
            "issn": "6",
            "pages": "1281--94",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "cytokines and HIV: a complex network of interactions that influence HIV pathogenesis",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Kinter",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Immunol Rev",
            "volume": "177",
            "issn": "",
            "pages": "88--98",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4+ T lymphocytes",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "M"
                    ],
                    "last": "Ebert",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Mccoll",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "J Immunol",
            "volume": "168",
            "issn": "1",
            "pages": "65--72",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Carroll",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "Science",
            "volume": "276",
            "issn": "5310",
            "pages": "273--279",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Progesterone-induced inhibition of chemokine receptor expression on peripheral blood mononuclear cells correlates with reduced HIV-1 infectability in vitro",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Vassiliadou",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Tucker",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Anderson",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "J Immunol",
            "volume": "162",
            "issn": "12",
            "pages": "7510--7518",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "RANTES potentiates antigen-specific mucosal immune responses",
            "authors": [
                {
                    "first": "Lillard",
                    "middle": [],
                    "last": "Jr",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "W"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "J Immunol",
            "volume": "166",
            "issn": "1",
            "pages": "162--171",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "CCR5 is characteristic of Th1 lymphocytes",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Loetscher",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "Nature",
            "volume": "391",
            "issn": "6665",
            "pages": "344--349",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "CCR5 and CCR2 gene polymorphisms in hypertensive patients",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Mettimano",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Br J Biomed Sci",
            "volume": "60",
            "issn": "1",
            "pages": "19--21",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "Phenotypic expressions of CCR5-delta32/ delta32 homozygosity",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "T"
                    ],
                    "last": "Nguyen",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "J Acquir Immune Defic Syndr",
            "volume": "22",
            "issn": "1",
            "pages": "75--82",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "J Immunol",
            "volume": "160",
            "issn": "8",
            "pages": "4018--4043",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "B"
                    ],
                    "last": "Huffnagle",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "J Immunol",
            "volume": "163",
            "issn": "9",
            "pages": "4642--4648",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "CCR5 mediates specific migration of Toxoplasma gondii-primed CD8 lymphocytes to inflammatory intestinal epithelial cells",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Luangsay",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Gastroenterology",
            "volume": "125",
            "issn": "2",
            "pages": "491--500",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "C"
                    ],
                    "last": "Dawson",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Am J Pathol",
            "volume": "156",
            "issn": "6",
            "pages": "1951--1960",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Susceptibility of CCR5-deficient mice to genital herpes simplex virus type 2 is linked to NK cell mobilization",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Thapa",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "A"
                    ],
                    "last": "Kuziel",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Carr",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "J Virol",
            "volume": "81",
            "issn": "8",
            "pages": "3704--3717",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "S"
                    ],
                    "last": "Machado",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Infect Dis",
            "volume": "191",
            "issn": "4",
            "pages": "627--663",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "L"
                    ],
                    "last": "Barr",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "J Microbiol Immunol Infect",
            "volume": "38",
            "issn": "4",
            "pages": "244--54",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "Variants of the chemokine receptor CCR5 are associated with severe bronchiolitis caused by respiratory syncytial virus",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hull",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "J Infect Dis",
            "volume": "188",
            "issn": "6",
            "pages": "904--911",
            "other_ids": {}
        },
        "BIBREF47": {
            "ref_id": "b47",
            "title": "CCR5 deficiency increases risk of symptomatic West Nile virus infection",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "G"
                    ],
                    "last": "Glass",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "J Exp Med",
            "volume": "203",
            "issn": "1",
            "pages": "35--40",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Kindberg",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J Infect Dis",
            "volume": "197",
            "issn": "2",
            "pages": "266--275",
            "other_ids": {}
        },
        "BIBREF49": {
            "ref_id": "b49",
            "title": "Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "P"
                    ],
                    "last": "Woitas",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Gastroenterology",
            "volume": "122",
            "issn": "7",
            "pages": "1721--1729",
            "other_ids": {}
        },
        "BIBREF50": {
            "ref_id": "b50",
            "title": "Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Ahlenstiel",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "J Hepatol",
            "volume": "39",
            "issn": "2",
            "pages": "245--52",
            "other_ids": {}
        },
        "BIBREF51": {
            "ref_id": "b51",
            "title": "Discussion on frequency of the HIV-protective CC chemokine receptor 5-Delta 32/Delta 32 genotype is increased in hepatitis C",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Klein",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Gastroenterology",
            "volume": "124",
            "issn": "5",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "HCV chronic infection and CCR5-delta32/ delta32",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mangia",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Gastroenterology",
            "volume": "124",
            "issn": "3",
            "pages": "868--877",
            "other_ids": {}
        },
        "BIBREF53": {
            "ref_id": "b53",
            "title": "Frequency of the 32-base pair deletion in the chemokine receptor CCR5 gene is not increased in hepatitis C patients",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Poljak",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Gastroenterology",
            "volume": "124",
            "issn": "5",
            "pages": "1558--60",
            "other_ids": {}
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Promrat",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Gastroenterology",
            "volume": "124",
            "issn": "2",
            "pages": "352--60",
            "other_ids": {}
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "High frequency of CCR5-delta32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Goedert",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "&apos;brien",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "R"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Gastroenterology",
            "volume": "124",
            "issn": "3",
            "pages": "867--875",
            "other_ids": {}
        },
        "BIBREF56": {
            "ref_id": "b56",
            "title": "CCR5 deficiency decreases susceptibility to experimental cerebral malaria",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Belnoue",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Blood",
            "volume": "101",
            "issn": "11",
            "pages": "4253--4262",
            "other_ids": {}
        },
        "BIBREF57": {
            "ref_id": "b57",
            "title": "Reduced macrophage infiltration and demyelination in mice lacking the chemokine receptor CCR5 following infection with a neurotropic coronavirus",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "G"
                    ],
                    "last": "Glass",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Virology",
            "volume": "288",
            "issn": "1",
            "pages": "8--17",
            "other_ids": {}
        },
        "BIBREF58": {
            "ref_id": "b58",
            "title": "The delta32 deletion of CCR5 receptor in rheumatoid arthritis",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "P"
                    ],
                    "last": "Cooke",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "Arthritis Rheum",
            "volume": "41",
            "issn": "6",
            "pages": "1135--1141",
            "other_ids": {}
        },
        "BIBREF59": {
            "ref_id": "b59",
            "title": "Association of rheumatoid arthritis with a functional chemokine receptor, CCR5",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Gomez-Reino",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Arthritis Rheum",
            "volume": "42",
            "issn": "5",
            "pages": "989--92",
            "other_ids": {}
        },
        "BIBREF60": {
            "ref_id": "b60",
            "title": "CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Zapico",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Genes Immun",
            "volume": "1",
            "issn": "4",
            "pages": "288--297",
            "other_ids": {}
        },
        "BIBREF61": {
            "ref_id": "b61",
            "title": "CC chemokine receptor 5 polymorphism in rheumatoid arthritis",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Garred",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "J Rheumatol",
            "volume": "25",
            "issn": "8",
            "pages": "1462--1467",
            "other_ids": {}
        },
        "BIBREF62": {
            "ref_id": "b62",
            "title": "CC chemokine receptor 5 influences late-stage atherosclerosis",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "P"
                    ],
                    "last": "Quinones",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Atherosclerosis",
            "volume": "195",
            "issn": "1",
            "pages": "92--103",
            "other_ids": {}
        },
        "BIBREF63": {
            "ref_id": "b63",
            "title": "Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Zernecke",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Blood",
            "volume": "107",
            "issn": "11",
            "pages": "4240--4243",
            "other_ids": {}
        },
        "BIBREF64": {
            "ref_id": "b64",
            "title": "Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "R"
                    ],
                    "last": "Veillard",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Circ Res",
            "volume": "94",
            "issn": "2",
            "pages": "253--61",
            "other_ids": {}
        },
        "BIBREF65": {
            "ref_id": "b65",
            "title": "CC chemokine receptor 5 and renaltransplant survival",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Fischereder",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Lancet",
            "volume": "357",
            "issn": "9270",
            "pages": "1758--61",
            "other_ids": {}
        },
        "BIBREF66": {
            "ref_id": "b66",
            "title": "Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Abdi",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "J Am Soc Nephrol",
            "volume": "13",
            "issn": "3",
            "pages": "754--762",
            "other_ids": {}
        },
        "BIBREF67": {
            "ref_id": "b67",
            "title": "Association of CCR5 delta32 with reduced risk of asthma",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "P"
                    ],
                    "last": "Hall",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Lancet",
            "volume": "354",
            "issn": "9186",
            "pages": "1264--1269",
            "other_ids": {}
        },
        "BIBREF68": {
            "ref_id": "b68",
            "title": "Delta 32 deletion of CCR5 gene and association with asthma or atopy",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Mitchell",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Lancet",
            "volume": "356",
            "issn": "9240",
            "pages": "1491--1493",
            "other_ids": {}
        },
        "BIBREF69": {
            "ref_id": "b69",
            "title": "No association between asthma or allergy and the CCR5Delta 32 mutation",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Nagy",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Arch Dis Child",
            "volume": "86",
            "issn": "6",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF70": {
            "ref_id": "b70",
            "title": "The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Sandford",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "J Allergy Clin Immunol",
            "volume": "108",
            "issn": "1",
            "pages": "69--73",
            "other_ids": {}
        },
        "BIBREF71": {
            "ref_id": "b71",
            "title": "Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Lentzsch",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Blood",
            "volume": "101",
            "issn": "9",
            "pages": "3568--73",
            "other_ids": {}
        },
        "BIBREF72": {
            "ref_id": "b72",
            "title": "Mesenchymal stem cells within tumour stroma promote breast cancer metastasis",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "E"
                    ],
                    "last": "Karnoub",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Nature",
            "volume": "449",
            "issn": "7162",
            "pages": "557--63",
            "other_ids": {}
        },
        "BIBREF73": {
            "ref_id": "b73",
            "title": "Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Lavergne",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "J Immunol",
            "volume": "173",
            "issn": "6",
            "pages": "3755--62",
            "other_ids": {}
        },
        "BIBREF74": {
            "ref_id": "b74",
            "title": "CCR5 expression influences the progression of human breast cancer in a p53-dependent manner",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ma\u00f1es",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "J Exp Med",
            "volume": "198",
            "issn": "9",
            "pages": "1381--1390",
            "other_ids": {}
        },
        "BIBREF75": {
            "ref_id": "b75",
            "title": "The density of coreceptors at the surface of CD4+ T cells contributes to the extent of human immunodeficiency virus type 1 viral replication-mediated T cell death",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Lelievre",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "AIDS Res Hum Retroviruses",
            "volume": "20",
            "issn": "11",
            "pages": "1230--1273",
            "other_ids": {}
        },
        "BIBREF76": {
            "ref_id": "b76",
            "title": "Inhibition of human immunodeficiency virus envelope glycoprotein-mediated single cell lysis by low-molecular-weight antagonists of viral entry",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Madani",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "J Virol",
            "volume": "81",
            "issn": "2",
            "pages": "532--540",
            "other_ids": {}
        },
        "BIBREF77": {
            "ref_id": "b77",
            "title": "Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "L"
                    ],
                    "last": "Tremblay",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Antimicrob Agents Chemother",
            "volume": "46",
            "issn": "5",
            "pages": "1336--1345",
            "other_ids": {}
        },
        "BIBREF78": {
            "ref_id": "b78",
            "title": "Response to treatment and disease progression linked to CD4+ T cell surface CC chemokine receptor 5 density in human immunodeficiency virus type 1 vertical infection",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gervaix",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "J Infect Dis",
            "volume": "185",
            "issn": "8",
            "pages": "1055--61",
            "other_ids": {}
        },
        "BIBREF79": {
            "ref_id": "b79",
            "title": "The immunological response to highly active antiretroviral therapy is linked to CD4+ T-cell surface CCR5 density",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Vincent",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "J Acquir Immune Defic Syndr",
            "volume": "43",
            "issn": "3",
            "pages": "377--385",
            "other_ids": {}
        },
        "BIBREF80": {
            "ref_id": "b80",
            "title": "Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Reeves",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Proc Natl Acad Sci",
            "volume": "99",
            "issn": "25",
            "pages": "16249--54",
            "other_ids": {}
        },
        "BIBREF81": {
            "ref_id": "b81",
            "title": "CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Heredia",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "AIDS",
            "volume": "21",
            "issn": "10",
            "pages": "1317--1339",
            "other_ids": {}
        },
        "BIBREF82": {
            "ref_id": "b82",
            "title": "Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Agrawal",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "J Virol",
            "volume": "78",
            "issn": "5",
            "pages": "2277--87",
            "other_ids": {}
        },
        "BIBREF83": {
            "ref_id": "b83",
            "title": "CXCR4-using virus detected in patients receiving maraviroc in the phase III studies MOTIVATE 1 and 2 originates from a preexisting minority of CXCR4-using virus. In: XVI HIV Drug Resistance Workshop",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Lewis",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Simpson",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Fransen",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF84": {
            "ref_id": "b84",
            "title": "Association between CCR5 genotype and the clinical course of HIV-1 infection",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "De Roda Husman",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "Ann Intern Med",
            "volume": "127",
            "issn": "10",
            "pages": "882--90",
            "other_ids": {}
        },
        "BIBREF85": {
            "ref_id": "b85",
            "title": "CCR5/delta(ccr5) heterozygosity: a selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype, NIAID AIDS Clinical Trials Group Protocol 241 Virology Team",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "T"
                    ],
                    "last": "D&apos;aquila",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "J Infect Dis",
            "volume": "177",
            "issn": "6",
            "pages": "1549--53",
            "other_ids": {}
        },
        "BIBREF86": {
            "ref_id": "b86",
            "title": "Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "J Virol",
            "volume": "72",
            "issn": "11",
            "pages": "9307--9319",
            "other_ids": {}
        },
        "BIBREF87": {
            "ref_id": "b87",
            "title": "Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "J"
                    ],
                    "last": "Aarons",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Virology",
            "volume": "287",
            "issn": "2",
            "pages": "382--90",
            "other_ids": {}
        },
        "BIBREF88": {
            "ref_id": "b88",
            "title": "Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1 alpha",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Maeda",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "J Virol",
            "volume": "74",
            "issn": "4",
            "pages": "1787--93",
            "other_ids": {}
        },
        "BIBREF89": {
            "ref_id": "b89",
            "title": "HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Trkola",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Proc Natl Acad Sci",
            "volume": "99",
            "issn": "1",
            "pages": "395--400",
            "other_ids": {}
        },
        "BIBREF90": {
            "ref_id": "b90",
            "title": "Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "E"
                    ],
                    "last": "Mosier",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "J Virol",
            "volume": "73",
            "issn": "5",
            "pages": "3544--50",
            "other_ids": {}
        },
        "BIBREF91": {
            "ref_id": "b91",
            "title": "Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Wolinsky",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Virology",
            "volume": "328",
            "issn": "1",
            "pages": "19--29",
            "other_ids": {}
        },
        "BIBREF92": {
            "ref_id": "b92",
            "title": "A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "T"
                    ],
                    "last": "Boyd",
                    "suffix": ""
                }
            ],
            "year": 1993,
            "venue": "J Virol",
            "volume": "67",
            "issn": "6",
            "pages": "3649--52",
            "other_ids": {}
        },
        "BIBREF93": {
            "ref_id": "b93",
            "title": "Expanded tropism of primary human immunodeficiency virus type 1 R5 strains to CD4(+) T-cell lines determined by the capacity to exploit low concentrations of CCR5",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Dejucq",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Simmons",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "R"
                    ],
                    "last": "Clapham",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "J Virol",
            "volume": "73",
            "issn": "9",
            "pages": "7842--7849",
            "other_ids": {}
        },
        "BIBREF94": {
            "ref_id": "b94",
            "title": "Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Lewis",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Mori",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Simpson",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "15th Conference on Retroviruses and Opportunistic Infections",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF95": {
            "ref_id": "b95",
            "title": "HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "D"
                    ],
                    "last": "Bieniasz",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "EMBO J",
            "volume": "16",
            "issn": "10",
            "pages": "2599--609",
            "other_ids": {}
        },
        "BIBREF96": {
            "ref_id": "b96",
            "title": "Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "Edinger",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "Proc Natl Acad Sci U S A",
            "volume": "94",
            "issn": "8",
            "pages": "4005--4015",
            "other_ids": {}
        },
        "BIBREF97": {
            "ref_id": "b97",
            "title": "Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Rucker",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Cell",
            "volume": "87",
            "issn": "3",
            "pages": "437--483",
            "other_ids": {}
        },
        "BIBREF98": {
            "ref_id": "b98",
            "title": "Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Agrawal",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Blood",
            "volume": "103",
            "issn": "4",
            "pages": "1211--1218",
            "other_ids": {}
        },
        "BIBREF99": {
            "ref_id": "b99",
            "title": "Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Karlsson",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "J Virol",
            "volume": "78",
            "issn": "21",
            "pages": "11807--11822",
            "other_ids": {}
        },
        "BIBREF100": {
            "ref_id": "b100",
            "title": "Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Soulie",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "AIDS",
            "volume": "22",
            "issn": "16",
            "pages": "2212--2216",
            "other_ids": {}
        },
        "BIBREF101": {
            "ref_id": "b101",
            "title": "In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Tsibris",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J Virol",
            "volume": "82",
            "issn": "16",
            "pages": "8210--8214",
            "other_ids": {}
        },
        "BIBREF102": {
            "ref_id": "b102",
            "title": "Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "G"
                    ],
                    "last": "Anastassopoulou",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "PLoS Pathog",
            "volume": "3",
            "issn": "6",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF103": {
            "ref_id": "b103",
            "title": "HIV resistance to CCR5 antagonists requires multiple mutations and is associated with reduced replication capacity",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Riley",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Wojcik",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "44th Interscience Conference on Antimicrobial Agents and Chemotherapy",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF104": {
            "ref_id": "b104",
            "title": "Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "V"
                    ],
                    "last": "Giorgi",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "J Infect Dis",
            "volume": "179",
            "issn": "4",
            "pages": "859--70",
            "other_ids": {}
        },
        "BIBREF105": {
            "ref_id": "b105",
            "title": "Chemokine-induced cell death in CCR5-expressing neuroblastoma cells",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Cartier",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "J Neuroimmunol",
            "volume": "145",
            "issn": "1-2",
            "pages": "27--39",
            "other_ids": {}
        },
        "BIBREF106": {
            "ref_id": "b106",
            "title": "CCL5-CCR5-mediated apoptosis in T cells: requirement for glycosaminoglycan binding and CCL5 aggregation",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "T"
                    ],
                    "last": "Murooka",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "J Biol Chem",
            "volume": "281",
            "issn": "35",
            "pages": "25184--25193",
            "other_ids": {}
        },
        "BIBREF107": {
            "ref_id": "b107",
            "title": "CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entryindependent mechanisms",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Dolan",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Nat Immunol",
            "volume": "8",
            "issn": "12",
            "pages": "1324--1360",
            "other_ids": {}
        },
        "BIBREF108": {
            "ref_id": "b108",
            "title": "Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Pandrea",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Blood",
            "volume": "109",
            "issn": "3",
            "pages": "1069--76",
            "other_ids": {}
        },
        "BIBREF109": {
            "ref_id": "b109",
            "title": "The relationship of CCR5 inhibitors to CD4 cell count changes: a meta-analysis of recent clinical trials in treatment-experienced subjects",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Wilkin",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Ribaudo",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Gulick",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "15th Conference on Retroviruses and Opportunistic Infections",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF110": {
            "ref_id": "b110",
            "title": "Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Lalezari",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J Infect Dis",
            "volume": "197",
            "issn": "5",
            "pages": "721--728",
            "other_ids": {}
        },
        "BIBREF111": {
            "ref_id": "b111",
            "title": "Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatmentexperienced patients: AIDS clinical trials group 5211",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "M"
                    ],
                    "last": "Gulick",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "J Infect Dis",
            "volume": "196",
            "issn": "2",
            "pages": "304--316",
            "other_ids": {}
        },
        "BIBREF112": {
            "ref_id": "b112",
            "title": "Changes in HIV-1 co-receptor tropism for patients participating in the maraviroc MOTIVATE 1 and 2 clinical trials",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Van Der Ryst",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Westby",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF113": {
            "ref_id": "b113",
            "title": "Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIVinfected adults",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Lalezari",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "AIDS",
            "volume": "19",
            "issn": "14",
            "pages": "1443--1451",
            "other_ids": {}
        },
        "BIBREF114": {
            "ref_id": "b114",
            "title": "GlaxoSmithKline ends aplaviroc trials",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Crabb",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "AIDS",
            "volume": "20",
            "issn": "5",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF115": {
            "ref_id": "b115",
            "title": "Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naive patients: results of the EPIC study (CCR100136)",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Yeni",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "HIV Med",
            "volume": "10",
            "issn": "2",
            "pages": "116--140",
            "other_ids": {}
        },
        "BIBREF116": {
            "ref_id": "b116",
            "title": "Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Strizki",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Antimicrob Agents Chemother",
            "volume": "49",
            "issn": "12",
            "pages": "4911--4920",
            "other_ids": {}
        },
        "BIBREF117": {
            "ref_id": "b117",
            "title": "Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment experienced adults: VICTOR-E1 48-week results",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Zingman",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Suleiman",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Dejesus",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "15th Conference on Retroviruses and Opportunistic Infections",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF118": {
            "ref_id": "b118",
            "title": "Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Schurmann",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "AIDS",
            "volume": "21",
            "issn": "10",
            "pages": "1293--1302",
            "other_ids": {}
        },
        "BIBREF119": {
            "ref_id": "b119",
            "title": "Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "J"
                    ],
                    "last": "Landovitz",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J Infect Dis",
            "volume": "198",
            "issn": "8",
            "pages": "1113--1135",
            "other_ids": {}
        },
        "BIBREF120": {
            "ref_id": "b120",
            "title": "Response to vicriviroc in HIV-infected treatment-experienced subjects using an enhanced Trofile HIV co-receptor tropism assay: reanalysis of ACTG5211 results",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Su",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Reeves",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Krambrink",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "48th Annual International Conference on Antimicrobial Agents and Chemotherapy",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF121": {
            "ref_id": "b121",
            "title": "An enhanced version of the trofile HIV coreceptor tropism assay predicts emergence of CXCR4 use in ACTG5211 vicriviroc trial samples",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Reeves",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Wilkin",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "15th Conference on Retroviruses and Opportunistic Infections",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF122": {
            "ref_id": "b122",
            "title": "UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Dorr",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Antimicrob Agents Chemother",
            "volume": "49",
            "issn": "11",
            "pages": "4721--4753",
            "other_ids": {}
        },
        "BIBREF124": {
            "ref_id": "b124",
            "title": "Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc (MVC) plus an optimized background therapy (OBT) versus placebo (PBO) plus OBT in the MOTIVATE 1 and 2 trials",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Nelson",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Fisher",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gonzalez-Garcia",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "XVII International AIDS Conference",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF125": {
            "ref_id": "b125",
            "title": "Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Fatkenheuer",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Nat Med",
            "volume": "11",
            "issn": "11",
            "pages": "1170--1172",
            "other_ids": {}
        },
        "BIBREF126": {
            "ref_id": "b126",
            "title": "Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Fatkenheuer",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "N Engl J Med",
            "volume": "359",
            "issn": "14",
            "pages": "1442--55",
            "other_ids": {}
        },
        "BIBREF127": {
            "ref_id": "b127",
            "title": "Maraviroc for previously treated patients with R5 HIV-1 infection",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "M"
                    ],
                    "last": "Gulick",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "N Engl J Med",
            "volume": "359",
            "issn": "14",
            "pages": "1429--1470",
            "other_ids": {}
        },
        "BIBREF128": {
            "ref_id": "b128",
            "title": "Efficacy and safety of maraviroc plus optimized background therapy in treatmentexperienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Hardy",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Reynes",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Konourina",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "15th Conference on Retroviruses and Opportunistic Infections",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF129": {
            "ref_id": "b129",
            "title": "The incidence of severe liver enzyme abnormalities and hepatic adverse events in the Maraviroc Clinical Development Programme. In: 11th European AIDS Conference/EACS",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "M"
                    ],
                    "last": "Hoepelman",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Ayoub",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Heera",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "9--10",
            "other_ids": {}
        },
        "BIBREF130": {
            "ref_id": "b130",
            "title": "A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Saag",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "J Infect Dis",
            "volume": "199",
            "issn": "11",
            "pages": "1638--1685",
            "other_ids": {}
        },
        "BIBREF131": {
            "ref_id": "b131",
            "title": "Quantification of HIV tropism by ''deep'' sequencing shows a broad distribution of prevalence of X4 variants in clinical samples that is associated with virological outcome",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Swenson",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Mo",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "16th Conference on Retroviruses and Opportunistic Infections",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF132": {
            "ref_id": "b132",
            "title": "A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (Zidovudine/Lamivudine), for the treatment of antiretroviral-naive subjects infected with R5 HIV 1: week 48 results of the MERIT study",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Saag",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Ive",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Heera",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "4th IAS Conference on HIV Pathogenesis",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF133": {
            "ref_id": "b133",
            "title": "Reanalysis of the MERIT study with the enhanced trofile assay (MERIT-ES)",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Saag",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Heera",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Goodrich",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF134": {
            "ref_id": "b134",
            "title": "Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2008. H-1232a",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF135": {
            "ref_id": "b135",
            "title": "CD4+ Cell restoration at 48 weeks in the Maraviroc (MVC) treatment-naive (TN) MERIT trial",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Lazzarin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Battegay",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Cooper",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "48th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC)",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF136": {
            "ref_id": "b136",
            "title": "Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Bouhlal",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "J Immunol",
            "volume": "166",
            "issn": "12",
            "pages": "7606--7617",
            "other_ids": {}
        },
        "BIBREF137": {
            "ref_id": "b137",
            "title": "CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Lopalco",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "J Immunol",
            "volume": "164",
            "issn": "6",
            "pages": "3426--3459",
            "other_ids": {}
        },
        "BIBREF138": {
            "ref_id": "b138",
            "title": "Potent antiretroviral activity of once-daily CCR5 antagonist INCB009471 over 14 days monotherapy",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Cohen",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Dejesus",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mills",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "XV International AIDS Conference",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF139": {
            "ref_id": "b139",
            "title": "TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Baba",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Antimicrob Agents Chemother",
            "volume": "49",
            "issn": "11",
            "pages": "4584--91",
            "other_ids": {}
        },
        "BIBREF140": {
            "ref_id": "b140",
            "title": "Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Heredia",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Proc Natl Acad Sci",
            "volume": "100",
            "issn": "7",
            "pages": "4179--84",
            "other_ids": {}
        },
        "BIBREF141": {
            "ref_id": "b141",
            "title": "Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Rodriguez-Frade",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "EMBO J",
            "volume": "23",
            "issn": "1",
            "pages": "66--76",
            "other_ids": {}
        },
        "BIBREF142": {
            "ref_id": "b142",
            "title": "Weekly and biweekly subcutaneous PRO 140 demonstrates potent, sustained antiviral activity",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Thompson",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Lalezari",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Saag",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "16th Conference on Retroviruses and Opportunistic Infections",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF143": {
            "ref_id": "b143",
            "title": "Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Heredia",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Proc Natl Acad Sci",
            "volume": "100",
            "issn": "18",
            "pages": "10411--10417",
            "other_ids": {}
        },
        "BIBREF144": {
            "ref_id": "b144",
            "title": "Thalidomide suppresses Up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4+ T cells in humans",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "P"
                    ],
                    "last": "Juffermans",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "J Infect Dis",
            "volume": "181",
            "issn": "5",
            "pages": "1813--1819",
            "other_ids": {}
        },
        "BIBREF145": {
            "ref_id": "b145",
            "title": "Statins disrupt CCR5 and RANTES expression levels in CD4+ T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Nabatov",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "PLoS ONE",
            "volume": "2",
            "issn": "5",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF146": {
            "ref_id": "b146",
            "title": "Redox regulation of chemokine receptor expression",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Saccani",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Proc Natl Acad Sci U S A",
            "volume": "97",
            "issn": "6",
            "pages": "2761--2767",
            "other_ids": {}
        },
        "BIBREF147": {
            "ref_id": "b147",
            "title": "Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocyte-derived macrophages: downregulation of CCR5 expression by cyclic adenosine monophosphate",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Thivierge",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "Blood",
            "volume": "92",
            "issn": "1",
            "pages": "40--45",
            "other_ids": {}
        },
        "BIBREF148": {
            "ref_id": "b148",
            "title": "Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5",
            "authors": [
                {
                    "first": "X",
                    "middle": [
                        "F"
                    ],
                    "last": "Qin",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Proc Natl Acad Sci",
            "volume": "100",
            "issn": "1",
            "pages": "183--191",
            "other_ids": {}
        },
        "BIBREF149": {
            "ref_id": "b149",
            "title": "Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Steinberger",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Proc Natl Acad Sci",
            "volume": "97",
            "issn": "2",
            "pages": "805--815",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Cons\u00e9quences virales de l'usage des antagonistes CCR5 : commutation des souches R5 vers les souches X4. Viral consequences of the use of CCR5 antagonists : R5 to X4 switch.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "et s'accompagne d'une augmentation du nombre des cellules T CD8+ circulant. Des \u00e9tudes suppl\u00e9mentaires sont en cours afin de justifier cette observation et prouver si elle est secondaire \u00e0 un v\u00e9ritable effet protecteur des antagonistes CCR5 sur les cellules T CD4+ et CD8+ et non pas juste \u00e0 une redistribution cellulaire ; l'\u00e9tude Maraviroc Immune Recovery Study (MIRS) \u00e9valuera le r\u00f4le du MVC dans la reconstitution immunitaire des patients ayant une CV ind\u00e9tectable et un nombre de CD4 inf\u00e9rieur \u00e0 200 ou 350 cellules/ml respectivement apr\u00e8s",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Diff\u00e9rents m\u00e9canismes de r\u00e9sistance des souches R5. Different mechanisms of resistance of R5 viral strains to CCR5 antagonists.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Tableau 1 Caract\u00e9ristiques des souches R5 et X4. Characteristics of R5 and X4 strains.",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "VCV chez des patients pr\u00e9trait\u00e9s, en \u00e9chec virologique et ayant un virus \u00e0 tropisme R5 d\u00e9termin\u00e9 par le test Trofile 1 [112]. Il s'agit d'un essai randomis\u00e9 en double insu, qui compara\u00eet quatre bras (VCV 5, 10 ou 15 mg/j versus placebo) associ\u00e9s \u00e0 un traitement optimis\u00e9 contenant 100-800 mg de ritonavir, pendant 48 semaines (Tableau 3). Le bras de 5 mg a \u00e9t\u00e9 arr\u00eat\u00e9 pr\u00e9cocement et augment\u00e9 \u00e0 15 mg \u00e0 cause des \u00e9checs virologiques et du nombre augment\u00e9 de commutations de cor\u00e9cepteur. Un \u00e9chec virologique a \u00e9t\u00e9 observ\u00e9 chez 27 \u00e0 33 % des patients sous VCV versus 86 % des patients sous placebo, ce qui prouve une activit\u00e9 antir\u00e9trovirale soutenue \u00e0 48 semaines \u00e0 partir de la dose de 10 mg de VCV par jour associ\u00e9e \u00e0 un traitement optimis\u00e9. Chez 18 patients, on a observ\u00e9 un changement de cor\u00e9cepteur ; 15 de ces changements \u00e9taient sous VCV (dont huit sous 5 mg de VCV), mais seulement neuf d'entre eux se manifestaient par un \u00e9chec virologique, ce qui correspond \u00e0 35 % d'\u00e9checs virologiques sous VCV. Une r\u00e9analyse des 116 \u00e9chantillons disponibles par Reeves et al. \u00e0 l'aide du test Trofile am\u00e9lior\u00e9 (ESTA ou Enhanced Sensitivity Trofile Assay) a reclass\u00e9 22 % (25/116) des souches R5 du screening en R5X4 ou X4, et 80 % (12/15) de celles d'entre elles ayant re\u00e7u du VCV ont \u00e9t\u00e9 en \u00e9chec virologique",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "ont analys\u00e9 les donn\u00e9es des patients en \u00e9chec virologique sous MVC. Chez ces 98 patients, 64 % avaient un virus \u00e0 tropisme R5X4 ou X4 au moment de l'\u00e9chec. Seuls 5 % des patients du bras placebo en \u00e9chec avaient un virus X4. Les patients en \u00e9chec virologique pr\u00e9coce \u00e9taient plus susceptibles d'avoir un virus X4, ce qui va dans le sens de la th\u00e9orie du \u00ab d\u00e9masquage \u00bb de virus d\u00e9j\u00e0 pr\u00e9existants [84], tandis que les \u00e9checs virologiques avec des virus R5 (ayant probablement acquis une r\u00e9sistance) surviennent approximativement 30 jours plus tard. Les virus utilisant le CXCR4 obtiennent \u00e0 nouveau un tropisme R5 apr\u00e8s 16 jours en moyenne d'arr\u00eat du MVC. Le MVC en addition \u00e0 un traitement optimis\u00e9 a \u00e9galement \u00e9t\u00e9 \u00e9valu\u00e9 chez des patients infect\u00e9s par des souches Tableau 5 R\u00e9sultats pool\u00e9s \u00e0 48 semaines des essais Motivate 1 et 2. Pooled 48-week results of Motivate 1 and Motivate 2 studies. TO) + MVC 300 mg QD ; TO + MVC 300 mg BID ; TO + placebo, chez des patients pr\u00e9trait\u00e9s et/ou infect\u00e9s par des virus avec r\u00e9sistances multiples (!2), \u00e9tant en \u00e9chec immunovirologique (CV moyenne > 5 log 10 copies/mL, taux m\u00e9dian des cellules T CD4+ < 50/mm 3 )[131]. L'analyse initiale \u00e0 24 semaines, pr\u00e9sent\u00e9e dans le Tableau 6, \u00e9voquait une efficacit\u00e9 virologique similaire dans les trois bras. Cependant, une analyse optimis\u00e9e de la diminution de la CV sous MVC + TO en fonction de la proportion de virus X4 \u00e9voquait que certains virus class\u00e9s D/M par le test Trofile 1 standard correspondant \u00e0 un taux de souches X4 inf\u00e9rieur \u00e0 10 % en s\u00e9quen\u00e7age \u00e0 haut d\u00e9bit, pourraient r\u00e9pondre au MVC[132]. Concernant la r\u00e9ponse immunologique, alors que l'augmentation moyenne du taux des cellules T CD4+ dans les deux bras de MVC semblait sup\u00e9rieure \u00e0 celle observ\u00e9e avec le placebo, cela n'\u00e9tait en fait significatif que dans le bras de MVC \u00e0 double prise quotidienne. Enfin, m\u00eame si la majorit\u00e9 des patients en \u00e9chec th\u00e9rapeutique sous MVC pr\u00e9sentaient un tropisme X4, il est \u00e0 noter que le gain en cellules T CD4+ chez les patients en \u00e9chec \u00e9tait similaire dans les trois bras et ind\u00e9pendant du tropisme au moment de l'\u00e9chec. Enfin, le profil de tol\u00e9rance a \u00e9t\u00e9 comparable dans les trois bras th\u00e9rapeutiques, notamment en ce qui concerne les pathologies tumorales malignes et l'h\u00e9patotoxicit\u00e9 ; aucun cas de lymphome n'a \u00e9t\u00e9 rapport\u00e9 durant l'\u00e9tude. Malgr\u00e9 ses limites (plus de 50 % des patients sous MVC ont abandonn\u00e9 l'\u00e9tude avant le terme pr\u00e9vu de 24 semaines et absence de stratification selon l'administration ou non de l'enfuvirtide), l'int\u00e9r\u00eat de cette \u00e9tude consiste au fait qu'elle ne retrouve pas d'effet n\u00e9faste en l'utilisation d'un r\u00e9gime antir\u00e9troviral contenant du MVC chez des patients infect\u00e9s par des souches non sensibles.Une derni\u00e8re \u00e9tude randomis\u00e9e, de phase III et analys\u00e9e en intention de traiter est l'\u00e9tude MERIT",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "Katerina Christina Psomas : interventions ponctuelles : activit\u00e9s de conseil pour Pfizer ; Pierre Corbeau : interventions ponctuelles : activit\u00e9s de conseil pour Pfizer, BMS et GSK ; Jacques Reynes (dans les cinq derni\u00e8res ann\u00e9es) : consultant ou membre d'un conseil scientifique ou intervenant dans un symposium ou investigateur principal d'un essai th\u00e9rapeutique d'un laboratoire pharmaceutique : Abbott, Astellas, Boehringer-Ingelheim, BMS, GSK, Gilead, MSD, Pfizer, Roche, Schering-Plough, Tibotec, parts sociales ou actions dans un laboratoire pharmaceutique : aucune. Tableau 7 R\u00e9sultats virologiques du PRO140 selon diff\u00e9rents sch\u00e9mas th\u00e9rapeutiques versus placebo. Virologic outcomes of three different doses of PRO140 comparatively to placebo.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}